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Novel Amino Acid and Ethanolamine Derivatives as Potential Tumor Imaging
Agents for Positron Emission Tomography
Abstract
Malignant tumors can be detected with high sensitivity and specificity by imaging their increased
metabolic rate for glucose, amino acids and fatty acids. Positron emission tomography (PET) with
glucose analog [18F]FDG, which utilizes increased glucose metabolism, has become a routine clinical test
for diagnosis, staging and restaging a variety of cancers. Despite the tremendous success of PET-FDG,
there are some well-known limitations of [18F]FDG such as high cerebral uptake, uptake in inflammatory
tissues, high excretion through urinary tract and low or negligent uptake in certain type of tumors.
Decades of nuclear medicine research have lead to development of other PET imaging agents to
overcome such limitations.
We examined two series of tracers targeting two different altered metabolic processes in the tumor cells
in order to improve on imaging properties of existing clinically utilized PET ligands. One series is 18F
labeled tyrosine and phenylalanine derivatives, which targets altered amino acid metabolism – increased
amino acids uptake and protein synthesis rate in cancer cells. We synthesized three new 18F labeled
fluoroalkyl tyrosine derivatives, in vitro studies in human glioblastoma cells of these tyrosine derivatives
indicated they were not very promising tumor-imaging agents since in comparison to clinically utilized
imaging agent O-(2-[18F]fluoroethyl)-L-tyrosine (FET), their uptake was much lower. We also synthesized
and evaluated L- and D-isomers of new phenylalanine derivatives, p-(2-[18F]fluoroethyl)-phenylalanine
(FEP) and p-(3-[18F]fluoropropyl)-phenylalanine (FPP) in comparison to clinically utilized FET and its Disomer. In vitro studies in 9L glioma cells as well as biodistribution and small animal PET imaging studies
demonstrated that L- isomer of FEP is comparable to FET and it is a potential useful tracer for tumor
imaging with PET. Comparison of L- and D-isomers of phenylalanine derivatives showed that D-isomers
did not have improved imaging properties than their corresponding L-isomers. Of all new aromatic amino
acid derivatives, L- isomer of FEP had the best outcome and is comparable to clinically established FET in
imaging rats bearing 9L tumor model.
The other series of tracers is 11C labeled ethanolamine amine derivatives, which targets the altered lipid
metabolism associated with increased cellular proliferation in tumors. Here, we developed 11C labeled
ethanolamine and two ethanolamine derivatives — N-methyl ethanolamine and N,N-dimethyl
ethanolamine. In vitro studies demonstrated that they could be more sensitive PET tracers than clinically
utilized [11C]choline for the imaging of phospholipids biosynthesis in tumors.
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ABSTRACT
NOVEL AMINO ACID AND ETHANOLAMINE DERIVATIVES AS
POTENTIAL TUMOR IMAGING AGENTS FOR POSITRON EMISSION
TOMOGRAPHY
Limin Wang
Hank F. Kung, Ph.D.
Datta E. Ponde, Ph.D.
Malignant tumors can be detected with high sensitivity and specificity by imaging
their increased metabolic rate for glucose, amino acids and fatty acids. Positron emission
tomography (PET) with glucose analog [18F]FDG, which utilizes increased glucose
metabolism, has become a routine clinical test for diagnosis, staging and restaging a
variety of cancers. Despite the tremendous success of PET-FDG, there are some wellknown limitations of [18F]FDG such as high cerebral uptake, uptake in inflammatory
tissues, high excretion through urinary tract and low or negligent uptake in certain type of
tumors. Decades of nuclear medicine research have lead to development of other PET
imaging agents to overcome such limitations.

We examined two series of tracers targeting two different altered metabolic
processes in the tumor cells in order to improve on imaging properties of existing
clinically utilized PET ligands. One series is

18

F labeled tyrosine and phenylalanine

derivatives, which targets altered amino acid metabolism – increased amino acids uptake
and protein synthesis rate in cancer cells. We synthesized three new

18

F labeled

fluoroalkyl tyrosine derivatives, in vitro studies in human glioblastoma cells of these
-v-

tyrosine derivatives indicated they were not very promising tumor-imaging agents since
in comparison to clinically utilized imaging agent O-(2-[18F]fluoroethyl)-L-tyrosine
(FET), their uptake was much lower. We also synthesized and evaluated L- and D-isomers
of new phenylalanine derivatives, p-(2-[18F]fluoroethyl)-phenylalanine (FEP) and p-(3[18F]fluoropropyl)-phenylalanine (FPP) in comparison to clinically utilized FET and its
D-isomer.

In vitro studies in 9L glioma cells as well as biodistribution and small animal

PET imaging studies demonstrated that L- isomer of FEP is comparable to FET and it is a
potential useful tracer for tumor imaging with PET. Comparison of L- and D-isomers of
phenylalanine derivatives showed that D-isomers did not have improved imaging
properties than their corresponding L-isomers. Of all new aromatic amino acid
derivatives, L- isomer of FEP had the best outcome and is comparable to clinically
established FET in imaging rats bearing 9L tumor model.

The other series of tracers is

11

C labeled ethanolamine amine derivatives, which

targets the altered lipid metabolism associated with increased cellular proliferation in
tumors. Here, we developed 11C labeled ethanolamine and two ethanolamine derivatives
— N-methyl ethanolamine and N,N-dimethyl ethanolamine. In vitro studies demonstrated
that they could be more sensitive PET tracers than clinically utilized [11C]choline for the
imaging of phospholipids biosynthesis in tumors.
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Chapter 1

Introduction
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1.1 Altered metabolism of cancer cells
Cellular metabolism within tumors is significantly different from that of
corresponding normal cells. Metabolism of neoplastic cells has been studied for many
decades, with the aim of designing new strategies for cancer prevention, diagnosis and
therapy, based upon the identification of tumor-specific enzymatic alterations. One of the
major metabolic changes in tumors is the high rate of aerobic glycolysis, also known as
the “Warburg effect”. Since Otto Warburg first discovered that tumor cells consume
glucose at higher rate than normal cells over 80 years ago [1], the “Warburg effect” has
been observed in many cancers. This increased glucose uptake in tumors provided the
basis for the development of glucose analog 2-[18F]fluoro-2-deoxy glucose (FDG) as a
positron emission tomography (PET) tracer [2], which is widely used clinically for
detection, staging and restaging of various cancers. Besides glucose, cancer cells also
have increased metabolism of nutrient such as amino acids and fatty acids that meet or
exceed the bioenergetic demands of cell growth and proliferation [3, 4]. Figure 1.1
presents an overview of the possible drivers, advantage and potential liabilities of altered
metabolism of cancer cells [5].
In recent years, there have been great advance in our understanding of the causes,
benefits and vulnerability of cancer cell metabolism. This advance has led to the
identification of new drug targets and facilitated the design of tumor specific metabolic
substrates. Research in profiling metabolites and enzymatic activities has enabled us to
develop diagnostic test and tracers for molecular imaging of cancer. In comparison to
other molecular imaging probes, tracers based on altered tumor metabolism could provide

-2-

unique information about integrated function of multiple transporters and enzymes in a
metabolic pathway [6].

Figure 1.1. The altered metabolism of cancer cells. Drivers (A, low oxygen and low pH microenviroment
and B, cancer-associated signaling pathways induce metabolic reprogramming). Advantages (C, increased
biosynthesis, D, avoid apoptosis and E, engage in local metabolite-based paracrine and autocrine
signaling). Potential liabilities (F, build up of toxic metabolites and G, high energetic demand). Adapted
from [5].

1.2 Imaging
Molecular imaging methods can non-invasively detect specific biological
processes that are aberrant in cancer. These methods can be used in detection, staging and
restaging of various cancers, evaluation and prediction of treatment response, and assist
in determining the prognosis of patients. Several modalities can be used for tumor cell
metabolic imaging, including PET, single photon emission computed tomography

-3-

(SPECT) and Magnetic Resonance Spectroscopy Imaging (MRS). Metabolic imaging is
increasingly fused with Computed Tomography (CT)/MRI for precise anatomical
localization [7, 8].
The development of MRSI is result of combining imaging techniques with
magnetic resonance spectroscopy (MRS). MRSI is used for detecting endogenous cellular
metabolites and can provide information for cancer diagnosis and treatment planning,
particularly for brain, breast and prostate cancers [9]. The application of MRSI is limited
by its low sensitivity and spatial resolution. An emerging technique, hyperpolarizing 13C
MRS imaging, dramatically enhances the sensitivity for detection and could further
extend the clinical use of MRS [10]. PET and SPECT, which are based on radiotracers,
are highly sensitive and can target a specific protein. The existing imaging modalities
mainly differ in five aspects: detection limit, spatial and temporal resolution, depth of
penetration, energy for imaging generation and availability of molecular probes [11].
Table 1.1 lists some of the general characteristics of available imaging modalities for
altered tumor metabolism.
Table 1.1. Comparison of modalities for tumor metabolic imaging [11, 12]
Imaging
Modality
MRSI
PET

SPECT

Isotopes
1

H,19F,
P,13C
11 18
C, F,
15
N,15O,
64
Cu,
124 68
I, Ga,
99m
Tc,
111
In, 123I
31

Radiation
spectrum in
image generation
Radiowave
High energy
γ rays
low energy
γ rays

Spatial
resolution

Temporal
resolution

Detection
limit

5 to 7 mm

mins to h

1-2 mm
(micro);
~ 4-5 mm
(clinical)
1-2mm
(micro);
>4mm
(clinical)

10s to mins

~10-3 to
~10-5 M
10-11 to
10-12 M

-4-

mins

10-10 to
10-11 M

Amount of
molecular
probe used
µg to mg
ng to µg

ng to µg

1.2.1. Radionuclide imaging
Radionuclide
radiopharmaceuticals

imaging

is

a

(radionuclides

specialty

of

incorporated

medical
into

imaging

that

uses

pharmaceutically-active

molecules) and relies on the process of radioactive decay for image generation. The
fundamental principle in nuclear imaging is the tracer principle invented in 1912 by
Nobel laureate George de Hevesy, who found that radioactive elements had identical
chemical properties to the nonradioactive form and therefore could be used to trace
chemical behavior in solutions or in the body [13]. Radioactive tracers allow the
distribution of labeled molecules to be followed, making it possible to study the
biochemistry within the various organs of the living body. Radionuclide imaging can
trace biochemical pathways without perturbing native biochemistry by using
submicromolar quantities of tracers thus having little chance of pharmacologic toxicity
and minimal radiation burden for the patients.
Of the available radioisotope imaging methods, PET has been gaining widespread
use thanks to its advantages over more conventional SPECT [14, 15]. PET provides a
superior combination of sensitivity and spatial resolution over single-photon imaging,
and allows accurate quantification of dynamic regional tracer concentration [14].
Furthermore, PET offers a greater range of radiopharmaceuticals for cancer imaging and
many PET isotopes have natural occurrence in biologically active molecules in contrast
to heavy isotopes used in SPECT, resulting in higher possibility of synthesizing
physiologically active tracers for PET. Now PET has become an increasingly important
tool for clinical oncology, so in this thesis work we mainly focus on developing imaging
agents for PET.
-5-

1.2.1.1 Positron Emission Tomography (PET)
PET detects high energy γ rays generated from positron emitting radionuclides.
The unstable radioisotopes undergo β+ decay and emit a positron (e+) and neutrino (v).
The emitted positrons travels a short distance (~1.1 mm) before they encounter electrons
(e+) in the surrounding medium, consequently annihilate and give off two coincident γ
rays with 511 Kev energy in opposite direction (Figure 1.2). These γ rays can be detected
within nanoseconds from each other, which defines the line of events in space and thus
the direction of flight. These events are registered and reconstructed into volumetric
images of radiotracers in vivo (Figure 1.3) [13].

Figure 1.2. Principles of positron emission tomography image acquisition.
(http://www.heartandmetabolism.org/images/HM34/HM3407gr1.gif)

A number of commonly occurring elements, such as carbon, oxygen, nitrogen,
and fluorine have positron-emitting isotopes. The stable nuclides of these elements can be
potentially replaced by their positron emitting counterparts in a number of compounds
-6-

and used as PET imaging agents. The short half-life of certain positron emitting nuclides
(t ½ for O15, N13 and C11 are 2, 10 and 20 min respectively) poses limit on the applications
of the radiotracers because their production requires an on-site cyclotron. Tracers with
isotopes of longer half-life such as

18

F (t ½ is 110 min) may overcome such limitation.

Advances in radiochemistry could lead to a greater number of radiotracers for PET [16].
PET currently has remarkable impact in the field of oncology as a diagnostic, staging and
restaging tool. Furthermore, PET can provide information pertaining to the drugs
effectiveness, the potential of PET to influence cancer therapy is significant and its role
in anti-cancer drug development and therapy is being increasingly recognized [17].

Figure 1.3. Principles of positron emission tomography. a. A cyclotron is used to produce short-lived
positron-emitting isotopes. b. Well-established molecular probe can be prepared using automated
synthesizers. c. The tracers (e.g. FDG) can be synthesized and intravenously injected. d. The PET scanner
can detect the coincident gamma-rays, and images can be reconstructed showing the location(s) and
concentration of the tracer of interest. e. Cross-sectional FDG-PET images are shown. Uptake in tumor (T),
brain (Br), myocardium (C) and renal excretion into the urinary bladder (B) are visible. Adapted from [2].
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1.3 Tumor metabolism imaging
Imaging altered tumor cell metabolism has been tremendously successful in
recent years. Numerous studies have shown that various cancers can be detected with
high sensitivity and specificity based on their increased metabolic rates for glucose,
amino acids or lipids [6] (Figure 1.4). A number of analogs of glucose, choline and amino
acids have been developed as PET or SPECT imaging agents and have shown promising
clinical results (Table 1.2). Here we will focus on discussion of altered tumor glucose,
amino acids and phospholipids metabolism and their clinical applications.

Figure 1.4 Simplified overview of metabolic processes targeted by PET. AA = amino acid; FAS = fatty
acid synthase; G6P = glucose-6-phosphate; LDH = lactate dehydrogenase; MCT = monocarboxylate
transporter; Ribose 5P = ribose-5-phosphate. Arrows indicates upregulation.

-8-

Table 1.2. Selected clinically used tumor metabolic imaging agents for PET
Modified from Vallabhajosula [18]
Radiotracers
Biochemical
Process
[18F]FDG
Glucose
metabolism
[11C]Methionine
(MET),
[18F]Fluoroethyl
tyrosine (FET)
[11C]Choline,
[18F]Fluorocholine
(FCH)
[11C]Acetate
[18F]Fluoroacetate

Amino acid transport and protein
synthesis

Mechanism of Uptake or
Localization
Facilitated diffusion via
glucose transporters. Substrate
for hexo- kinase in glucose
metabolism
Transport into the cells
involves amino acid carrier
protein

Reported clinical
applications
Colorectal cancer, melanoma, Non-small cell
lung cancer, lymphoma,
et al. [18]
Brain tumors et al. [19,
20]

Membrane
synthesis

Substrates for choline kinase
in choline metabolism

Prostate cancer, brain
tumors et al.[21, 22]

Lipid synthesis

Acetate is activated to acetylCoA in both the cytosol and
mitochondria by acetyl-CoA
synthetase

Prostate cancer, brain
tumors et al. [23]

1.4 Tumor glucose metabolism and its clinical applications
1.4.1 Tumor glucose metabolism and the development of FDG
The most well known altered metabolism in tumor cells is increased aerobic
glycolysis (the Warburg effect). In comparison to normal cells, cancerous cells mainly
use glycolysis without entering kreb cycle in mitochondria even when oxygen is present
[24]. It seems to be paradoxical as pointed out by Gatenby [25] since cancer cells have
high demand for energy while glycolytic metabolism is very inefficient (producing only 2
mol of adenosine triphosphate (ATP) per mole of glucose vs. 36 mol of ATP per mole of
glucose for the citric acid cycle) and generates an acidic, potentially toxic environment
[26]. It is suggested that increased glycolysis confers survival and growth advantages for
cancer cells and it is an adaptation to intermittent hypoxia in malignant lesions [27].
Furthermore, increased glycolysis is result of oncogenic action. Re-programming of gene
expression may be an important mechanism for altered tumor cell metabolism. Activation
-9-

of oncogenes such as (e.g. HIF1, Akt, Myc [28-30]) or loss of tumor suppressor genes
(e.g. p53 [31]) could be the underlying mechanism for increased glycolysis in cancer
cells.

Figure 1.5. The cellular metabolism of glucose and [18F]FDG. G6P = glucose-6-phosphate; LDH = lactate
dehydrogenase; MCT = monocarboxylate transporter. Arrows indicates upregulation or downregulation.

1.4.2 Clinical success and limitations of FDG-PET
FDG-PET, which is based on altered tumor glucose metabolism, is the most
widely used imaging method by far. It is a routine clinical test for diagnosing, staging,
restaging and monitoring therapy for a variety of cancers including lung cancer,
lymophoma, colorectal cancer et al [18]. Uptake and trapping of FDG results from
upregulation of glucose transporters (GLUT, notably GLUT1 [32], GLUT3 [33] and
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GLUT12 [34]) and hexokinase [35]. FDG is transported across the cell membrane by
sodium independent, facilitative glucose transporters and is then phosporylated by
hexokinase to FDG-6-phosphate (as in Figure 1.5). In contrast to glucose-6-phosphate,
which can further be metabolized to fructose-1, 6-biphosphate via glycolysis pathway,
FDG-6-phosphate cannot be further metabolized because of substitution of F atom at C2
position. As a result of lack of transporters for FDG-6-phosphate, it is trapped and
steadily accumulates in metabolically active tumor cells.
The current clinical applications of FDG in cancer diagnosis and management are
very broad [36]. Despite the tremendous success of FDG, it has several well-known
drawbacks that limit its applications: 1) the normal brain depends exclusively on glucose
metabolism for energy demand. As a result, normal cerebral cortex has high
accumulation of FDG. In case of diagnosis of brain tumor, this leads to low contrast
making differentiation of tumor from surrounding grey matter difficult; 2) inflammatory
cells and macrophages have same level of uptake of FDG as tumor cells, this could cause
false-positive results [37]; 3) some tumors do not have increased uptake of FDG thus
could not be detected by FDG-PET. The reasons for lack of uptake include relatively low
glucose metabolism, as seen in prostate cancer, high mucin content, low proliferation
rates and necrosis [38]; 4) FDG has high urinary excretion, because pelvic malignancies
such as prostate cancer, urinary bladder carcinoma and renal cell carcinoma, are close to
the urinary route, thus can not be satisfactorily visualized via FDG-PET [39]. To
overcome these limitations of FDG, various radiopharmaceuticals have been developed
for PET studies. We will focus on the advance of amino acid and choline based ligands as
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tumor imaging agents in the following sections. The new tracers we developed in this
thesis work will be discussed in the meantime.

1.5 Developing new PET tracers for tumor metabolism imaging
Developing new PET tracers is a multidisciplinary process involving selecting
desirable targets, organic synthesis, radiolabeling, and in vitro/in vivo biological
evaluations before tracers could be used in preclinical or clinical settings [40]. A
promising imaging agent for aberrant tumor metabolism should have but not limited to
the following properties: 1) ease of synthesis of radioactive ligands and their
corresponding non-radioactive precursors and standards; 2) high affinity and selectivity
towards enzymes associated with altered tumor metabolism; 3) good in vivo stability; 4)
desirable in vivo pharmacokinetics (e.g. fast accumulation in targets, appropriate
clearance rate). To evaluate the potential of new tracers as PET imaging agents, in vitro
and/or in vivo tests should be performed. In vitro tests such as uptake studies provide a
way to test tracers’ accumulation in target tumor cells. Protein binding and competition
studies allow assessing the affinity and/or selectivity of tracers to the target enzymes.
Biodistribution and small animal PET imaging studies in rat or mice tumor models enable
evaluation of in vivo pharmacokinetics of the PET tracers. Further metabolites analysis to
study tracers’ in vivo stability and metabolic pathways could be carried out via HPLC
analysis of plasma sample after certain time post-injection. Preclinical evaluations are
important and provide insightful information before the new PET tracers go into
clinically trials. But the data acquired in these biological evaluations need to be
interpreted with caution considering the interspecies difference.
- 12 -

1.5.1 Tumor amino acid metabolism and novel amino acid based tracers
1.5.1.1 Tumor amino acid metabolism

Figure 1.6. Tumor cell amino acid metabolism. There are at least four amino acid transporters that are
generally upregulated in tumor cells: ASCT2, LAT1/4F2hc, xCT/4F2hc, and ATB0,+. All four transporters
participate in providing tumor cells with amino acids necessary for protein synthesis. EAA, essential amino
acids; Glu, glutamate; αKG, α-ketoglutarate. Adapted from [41].

Amino acids (AAs) are not only essential for protein synthesis, but also function
as an energy source and precursors for biomolecules such as nucleotides, amino sugars
and serotonin. Tumor cells have increased transport of amino acids and/or protein
synthesis to support their growth and survival (Figure 1.6). The essential mechanisms
involved in uptake of amino acids are the carrier-mediated transport into cells and the
esterification of the amino acids to form the aminoacyl-t-RNA, which forms the
polypeptide chain in the ribosome (incorporation into protein). Of these two mechanisms,
transport and incorporation into protein, uptake of amino acid tracers is generally
- 13 -

dominated by carrier-mediated transport [42-44]. So amino acid transporters have been
the main focus of the development of amino acid tracers in recent years.
Amino acid transporters are classified into distinct systems based on ion
dependence, substrate selectivity, sensitivity to selective inhibitors, kinetics, regulatory
properties et al [45]. A number of amino acid transport systems have been shown to be
upregulated in a variety of cancer cell lines and play important roles for tumor growth
and survival (Table 1.3). System L (LATs), in particular its subtype LAT1, has attracted
special interest. It is a promising target for imaging agents and cancer therapy for a
number of reasons: 1) elevated expression correlates well with tumor growth and poor
prognosis [46]; 2) low expression in normal and inflammatory tissues ensuring high
tumor specificity [47]; 3) pivotal in transport of amino acids through blood-brain barrier
[48]; 4) plays important role in transporting certain anti-cancer drugs such as melphalan
[49]; 5) inhibition of LAT1 suppresses cancer growth [50]; 6) substrates of LATs have
demonstrated promising clinical imaging results (as shown in Table 1.4).
Table 1.3. Major amino acid transport system upregulated in cancer cells
System

Protein

Na+ dependence

Substrate specificity

Comments

A

SAT1
SAT2
SAT3
ASCT1
ASCT2

Na+ dependent

Short, polar, straight chain
AAs such as Gly and Ala,

Na+ dependent

Small polar AAs such as Ala,
Ser,Cys, Gln et al

B0,+

ATB0,+

Na+ dependent

Neutral and cationic amino
acids such as Gln, Lys et al,

L

LAT1
LAT2
LAT3
LAT4

Na+ independent

Large branched neutral AAs
such as Phe, Tyr, Met, Trp et
al

Influx transporter, inducible by
starvation, hormones, growth
factors [51]
Upregulation observed in
prostate cancer and colorectal
carcinoma [52, 53]
Broad substrate selectivity,
accepts 18 of 20 natural amino
acids, induced in cervical cancer
and colorectal cancer [54, 55]
Broad substrate selectivity,
subytpe LAT1 can accept Disomer, upregulation has been
observed in brain, colon, lung,
liver and skin cancers [56]

ASC
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1.5.1.2 Clinical applications of amino acid based tracers
H311C

S
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HO
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NH2

123
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HO
IMT

COOH
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NH2

HO

I
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O

FET

FPro

SPECT tracers

PET tracers

Figure 1.7. Structures of clinically utilized amino acid based tracers.

Table 1.4. Selected clinically utilized amino acid tracers and their uptake mechanism.
Tracers

Transport
mechanism

Clinical applications

Comments

MET

A; LATs [57]

Brian tumors, head and neck,
lung, malignant lymphomas,
and breast cancer

Short half life, high excretion through
bladder, complicate in vivo metabolism

IMT

LATs [58, 59]

Brian tumor, non-small cell
lung cancer

FPro

A; PAT1 [60]

Brain tumors

May not differentiate low grade glioma
from non-neoplasmatic lesions or high
grade gliomas
Uptake is limited to areas of blood brain
barrier disruption

FDOPA

LATs [61]*

Parkinson’s disease

FACBC

LATs [62]

FET

LATs; B0,+
contribute to a
lesser extent [20]

Substrate for aromatic amino acid
decarboxylase, undergoes extensive in
vivo metabolism with multiple metabolites
Brain tumor, prostate cancers
Low urinary excretion
and renal cell carcinomas
Brain tumor,
Efficient labeling process, limited
head and neck cancer
applications in extracranial tumors
(negligible uptake in peripheral tumors
such as breast cancer, lung cancer,
lymphomas)

Currently, the most widely used amino acid based tracer is [11C]methionine
(MET), which has proven useful for imaging brain, head and neck, lung, malignant
lymphomas, and breast cancer [19, 63]. However, it has high uptake in liver, pancreas,
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and intestine and is excreted through the bladder, characteristics that interfere with tumor
imaging in the abdominal region and in the region of the bladder or prostate. Its uptake
also

reflects

non-protein

metabolic

pathways

such

as

transamination

and

transmethylation, which makes imaging kinetic analysis difficult [64]. In additional, short
half-life of 11C necessitates onsite cyclotron, limiting its clinical applications. This led to
the development of non-natural amino acid labeled with longer half-life isotopes such as
18

F and 123I. A variety of tyrosine and phenylalanine derivatives have been developed for

tumor imaging (Figure 1.7) such as 3-[123I]-α-methyl-L-tyrosine (IMT) [59], 3[18F]fluoro-α-methyl-L-tyrosine (FMT) [65], 3,4-dihydroxy-6-[18F]fluorophenylalanine
(FDOPA) [66], and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) [20]. Other compounds such
as cyclic 1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (FACBC) [67] and proline
derivatives cis-4-[18F]fluoro-L-proline (FPro) [68] have also been clinically used. As we
can see from Table 1.4, system L represents the major underlying uptake mechanism for
these amino acid tracers.

1.5.1.3 Design of novel aromatic amino acids derivatives
As we stated in section 1.5.1, system L, in particular its subtype LAT1, is a
promising target for developing amino acid based tracers. For a radiotracer to be
clinically successfully and reflect specific protein activity associated with altered tumor
metabolism, it should have efficient radiolabeling process, high selectivity and/or affinity
towards target protein, desirable in vivo kinetics, and stability in vitro and in vivo. From
studying substrate recognition for LAT1 [69], it is proposed that for a ligand to be
substrate for LAT1, it should satisfy the following requirements (as shown in Figure 1.8):
- 16 -

1) have a free carboxyl and an amino group; 2) The carbonyl oxygen in the binding site
needs an appropriate polarity and must not participate in hydrogen bonding; 3) desirable
hydrophobic interaction in the side change.

Figure 1.8. Proposed model for the substrate-binding sites of LAT1. 3,4-dihydroxy L-phenylalanine
(DOPA) used as the model compound. Adapted from [68].

There are no extensive quantitative studies on structure-activity of LATs. In
search of new amino acid based tracers with potential improved imaging characteristics,
we chose one of clinically established LATs L-[18F]FET, as our reference tracer and
parent compound for further modification. L-[18F]FET is one of the first

18

F labeled

amino acid based tracers that could be produced in a large quantity for clinically use and
satellite distribution similar to FDG. It has high radiochemical yield, low accumulation in
normal brain and peripheral tissues, rapid tumor uptake, and good in vivo stability and
has established clinically applications in imaging brain tumors and head and neck cancer
[20, 70, 71]. However, it has negligible accumulations in many extracranial tumors and
- 17 -

high urinary excretion, which limit its applications [72]. Using the fluoroalkyl tyrosine
core structure of L-[18F]FET as the lead, modifications (as Figure 1.9) were made to
structure to probe the affinity and selectivity for amino acid transporters.
COOH
18F

COOH

COOH
18F

NH2

18F

NH2

NH2

p-(3-[18F]fluoropropyl)L-phenylalanine
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L-FEP

COOH
18F

D-phenylalanine
D-FEP

L-FPP

NH2
p-(3-[18F]fluoropropyl)D-phenylalanine

p-(2-[18F]fluoroethyl)-

D-FPP

Fluoroalkyl Phenylalanine Derivatives
alteration of alkyl chain
amide

COOH
18F

O

NH2

!-methyl substitution
D isomer

alteration on aromatic ring
L-FET

18

F

18

O
COOH
H2N

F
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18

O
N

F

O

COOH
H2N

H2N

CONH2

O-(2-[18F]fluoroethyl) methyl tyrosine O-(2-[18F]fluoroethyl)-2-L-azatyrosine O-(2-[18F]fluoroethyl)-tyrosine amide

FEMT

FEAT

FETA

Fluoroalkyl Tyrosine Derivatives
Figure 1.9 Design of novel aromatic amino acid derivatives as potential PET imaging agents

In designing this new series of amino acid tracers, we kept alkyl chain as the
linker for

18

F. In this way,

18

F can be incorporated in to the target molecule through a

direct nucleophilic reaction to form fluroalkyl side chain, which generally has high
radiochemical yield. From α-methyl substitution (FEMT), alteration in aromatic ring
(FEAT) and change of carboxyl group to amide (FETA), a series of tyrosine derivatives
were prepared. Via alteration in alkyl chain (i.e. elimination of oxygen atom may enhance
the hydrophobic interaction with LAT1), we developed a series of phenylalanine
derivatives (FEP and FPP). Because LAT1 could transport D-isomers of phenylalaine, we
also prepared the D-isomers of the phenylalanine derivatives. One of the FET analog, L- 18 -

isomer of FEP was found to be transported predominately via LATs and demonstrated
preference towards subtype LAT1. The selectivity for LATs does not guarantee that a
radiotracer will be potential useful imaging agents for increased amino acid transport
activity in tumor cells. In vivo studies such as kinetic studies and imaging studies need to
be executed to determine whether tumors could be appropriately imaged.

1.5.2 Tumor phospholipid metabolism and new ethanolamine tracers
1.5.2.1 Tumor phospholipid metabolism

Figure 1.10 Choline phospholipid metabolism. Metabolites are given in bold letters. CCT =
CTP:phosphocholine cytidylyltransferase; ChoT = choline transporters; ChoK = Choline kinase; PCho =
phosphocholine; PtdCho = phosphoatidyl choline; Arrows indicates upregulation.

Phosphoglycerides are important in formation of cellular and organelle
membranes in rapidly growing tumors. The elevation of phosphocholine (PCho) or
phosphoethanolamine (PEtn) is one of widely established characteristics of cancer cells
[73]. Numerous in vivo and in vitro 1H and

31

P MR spectroscopic studies have detected
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high levels of PCho or PEtn, or both, in a variety of cancers such as breast, prostate, and
different types of brain tumors, whereas low levels of these metabolites were found in
corresponding normal tissues [74, 75]. These studies demonstrate the significance of
phospholipid precursors and catabolites as biochemical indicators of tumor progression
and response to therapy. Most notable mechanisms underlying the increased PCho levels
(as in Figure 1.10) include increased expression and activity of choline kinase [76, 77], a
higher rate of choline transport [78], and increased phospholipase (PLD) [79]. Choline
kinase (ChoK) phosphorylates free choline to PCho in the CDP-Choline pathway (or
kennedy pathway). ChoK is considered to be an important target for cancer because it
regulates oncogene activation and correlates with tumor growth and prognosis [80, 81].

1.5.2.2 Clinical applications of choline and its derivatives
H 311C
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N

11

C-Choline (CH)

18

F

N

18F

N
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N
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18F-fluoromethylethylcholine

18 F

OH
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F-fluoropropylethylcholine (FPC)

(FMEC)

Figure 1.11. Choline and its derivatives as PET imaging agents

Choline ([11C]CH) and its derivatives (Figure 1.11) have been developed as
biomarkers for aberrant choline phospholipids metabolism in tumors. In particular,
[11C]CH and [18F]FCH-PET are valuable tools for imaging prostate cancer, breast
carcinoma, and brain tumors [82, 83]. But [11C]CH and its derivatives have limitations
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including high bladder uptake and high radiation dose to kidney, liver and spleen [84].
The most activity accumulates into the liver and kidney because choline oxidase oxidazes
choline into betaine and causes activity to be trapped there.

1.5.2.3 Rational for new 11C labeled ethanolamine and its derivatives
H311C

NH211CH2CH2OH
[11C]ethanolamine (EA)

N
H

H311C

OH

[11C]N-methyl ethanolamine (MEA)

N

OH

[11C]N, N-Dimethyl ethanolamine (DMEA)

Figure 1.12. 11C labeled ethanolamine and its derivatives

Elevated PEtn concentration is found to be even higher than PCho in a variety of
tumors

[85,

86].

Ethanolamine

is

subject

to

biosynthetic

pathway

for

phosphoatidylethanolamine (major phospholipid component in cell membrane) similar to
choline [87, 88]. This might be an indication that ethanolamine, the precursor of PEtn,
could be a potential useful and more sensitive imaging agents than choline for tumor
phospholipids metabolism.
We first conducted preliminary studies using 14C labeled ethanolamine and N, N’dimethyl ethanolamine to validate the potential of ethanolamine tracers for tumor
detection. The results demonstrated that

14

C labeled ethanolamine tracers were taken up

significantly better (2-7 fold) than [14C]choline in a wide variety of tumor cells including
colorectal cancer (HCT116), prostate (PC-3), melanoma (A375 and 1618), glioblastoma
(SF767, A172), and lymphoma (DLCL2) [89]. Since
behave the same as their natural and

14

11

C labeled compound would

C labeled counterpart, we hypothesize that

11

C

labeled ethanolamine and its derivatives could potentially be more sensitive biomarkers
for tumor phospholipid metabolism than [11C]CH. We then proceeded with the synthesis
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and biological evaluations of the series of

11

C labeled ethanolamine and its derivatives

(Figure 1.12).

1.6 Scope of the thesis research
The ultimate goal of this thesis work is to develop new PET tracers with better
imaging properties than current clinically utilized imaging agents for certain types of
tumors such as brain tumor and prostate cancer based on altered tumor metabolism. This
thesis work included early radiopharmaceuticals discovery phase up to preclinical PET
imaging studies in rats. Chapter two to four describes the development of new 18F labeled
aromatic amino acid derivatives as potential PET imaging agents based on tumor amino
acid metabolism. Chapter two covers the synthesis of a series of new fluoroethyl tyrosine
derivatives and their in vitro characterization through cell uptake studies in the human
glioma cell line. Chapter three describes the preparation of fluoroalkyl phenylalanine
derivatives and their biological evaluations including in vitro evaluations through cell
uptake studies and uptake mechanism characterization and in vivo characterization
through biodistribution and small animal PET imaging studies. Chapter four describes
comparative studies of D- and L-isomers of fluoroalkyl phenylalanine derivative via in
vitro cell uptake and transport characterization and in vivo PET imaging studies in rats.
Chapter five covers the development of new

11

C labeled ethanolamine derivatives as

potential PET tracers based on tumor phospholipid metabolism. Preliminary studies of
14

C ethanolamine and its derivatives, labeling of

prostate cancer cell lines are described.
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11

C ligands and in vitro studies in

1.7 Clinical significance of this work
Metabolic imaging has a significant impact on patient management by improving
tumor staging, treatment planning and monitoring response to therapy. There is growing
evidence demonstrating a close link between oncogene activation and metabolic change
in cancer cells. Altered tumor metabolism is increasingly considered to represent a group
of promising therapeutic targets, and tumor metabolic imaging provides a way to monitor
such

targeted

therapies

[3].

Increased

amino

acid

transporter

activity

and

choline/ethanolamine phospholipids metabolism are observed in a wide variety of
cancers. It is our hope that these novel metabolic tracers could provide better tools for
imaging altered amino acid transport and phospholipid metabolism in tumors.
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Chapter 2

Synthesis and in vitro evaluation of 18F labeled
tyrosine derivatives as potential PET imaging agents
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2.1 Introduction
A number of classes of metabolically based radiotracers such as radiolabeled
glucose, amino acids, fatty acids and their analogs were developed for tumor imaging and
have shown tremendous success in recent years. [18F]fluorodeoxyglucose (FDG), which
utilizes upregulated aerobic glycolysis in tumor cells [1], is routinely used in clinics for
detecting, staging and restaging of lymphomas [2] and many solid tumors [3]. However,
it has certain limitations such as high uptake in the cerebral cortex and non-specific
accumulation in inflammatory tissues [4]. In search of new imaging agents, a variety of
radiolabeled amino acids were prepared based on increased amino acid uptake and
protein metabolism in cancer cells. Numerous studies have demonstrated that amino acid
based tracers show better results than FDG in detecting and delineating certain tumors,
particularly in brain tumors [5].
Currently, the most commonly used labeled amino acid in PET is [11C]methionine
(MET) [6, 7]. Despite the success, its susceptibility to multiple metabolic pathways
complicates the pharmacokinetic analysis [8, 9] and its short half-life (20.3 min) limits its
clinical applicability. To overcome these disadvantages, a number of 18F (half-life 109.8
min) labeled amino acid analogs such as O-(2-[18F]fluoroethyl)-L-tyrosine (FET, [18F]1)
[10], L-3-[18F]fluoro-α-methyl tyrosine (FMT) [11], 6-[18F]fluoro-L-dihydroxy phenylalanine (FDOPA) [12], and anti-1-amino-3-[18F]fluorocyclobutyl-1-carboxylic acid
(FACBC) [13, 14] were developed. In particular FET ([18F]1), is a successful 18F labeled
amino acid tracer and it has been used in imaging brain tumors and head-neck carcinomas
for diagnosis and therapy planning [15, 16].
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Several close analogs of FET ([18F]1), such as O-(18F]fluoromethyl)-L-tyrosine
[17], O-(3-[18F]fluoropropyl)-L-tyrosine [18] and O-(3-[18F]fluoropropenyl)-L-tyrosine
[19] have been developed and evaluated. The uptake of these structurally similar tyrosine
derivatives in tumor cells is most likely attributed to elevated amino acid transporter
activity, in particular system L amino acid transporters (LATs) [5, 20, 21], a Na+
independent transport system which mediates transport of branched and aromatic amino
acids [22]. LAT, generally upregulated in many cancer cell lines, is a target for
development of tumor imaging agents [23-25]. System L has broad substrate selectivity;
substitutions on aromatic ring with fluorine, hydroxy or fluoroalkyl group as well as
substitutions on α-hydrogen with methyl are generally tolerated, this enables developing
a variety of structurally similar analogs as potential LATs substrates [26].
COOH

!-methyl substitution
18F

O

reference ligand

COOH
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O

NH2
FEMT
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Figure 2.1. FET ([18F]1) and its new analogs.

To pursue aromatic amino acid derivatives with better tumor-avid properties than
FET ([18F]1) and exploring the structure-activity relationships (SAR) of LATs, three new
18

F tyrosine derivatives were synthesized and evaluated (Figure 2.1): O-(2-

[18F]fluoroethyl)-α-methyl

tyrosine

(FEMT,
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[18F]2),

O-(2-[18F]fluoroethyl)-2-L-

azatyrosine (FEAT, [18F]3), and O-(2-[18F]fluoroethyl)- L-tyrosineamide (FETA, [18F]4).
FEMT ([18F]2) could be considered as fluoroalkyl derivative of well established SPECT
tracer 3-[123I]iodo-α-methyl-L-tyrosine (IMT).[27] We reasoned that FEAT ([18F]3)
might have specific uptake in cancer cells, because its analog 2-azatyrosine was reported
to show antitumor activity and could reverse the ras transforming cancer cells to normal
cell without significant effect on the growth of normal cells [28]. The amide derivative
FETA ([18F]4) was synthesized in hope that higher lipophilicity of [18F]4 may lead to
improved pharmacokinetics compared to FET ([18F]1), such as reduced excretion through
urinary tract.

2.2 Results and discussion
2.2.1 Synthesis of precursors and authentic standards for radiotracers
a

HO
COOH

b

HO
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COOBut
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H2N

BocHN
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d
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Scheme 2.1. Initial synthetic route of FEMT 2. Reagents and conditions: a) (Boc)2O,
dioxane/H2 O, details as listed in Table 2.1; b) tert-butyl 2,2,2-trichloroacetimidate, BF3.Et2 O,
CH2Cl2/THF, 1 d, 45%; c) TsO(CH2)2 OTs, K2CO3 , DMF, 70 oC, 26 h, 70 oC, 13%; d)
FCH2CH2 Br, NaH, DMF,0 oC to 5 oC, 7 h, 88%; e) TFA, CH2 Cl2, 30 min, 40%; f) tert-butyl
trichlorloacetimidate, CH2Cl2/cyclohexane, BF3.Et2 O, rt to 50 oC, 3 d, 21%.
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Table 2.1: Boc protection result of 5 under various conditions:
Base

Temperature (oC )

Reaction time

Yield (%)

NaHCO3/NaOH

25

2d

9

Me4NOH

25

5d

26

Et3N

25

7d

21

Et3N

50

2d

30

a

HO

HO

COOH
H2N

H2N
5

COOMe .HCl

b

HO
COOMe
BocHN
12

11

c

d
F

e

O
COOH
H2N
2

F

TsO

O
COOMe
BocHN
14

O
COOMe
BocHN
13

Scheme 2.2. Improved synthesis of FEMT 2. Reagents and conditions: a) SOCl2, MeOH, 0 oC to
reflux, 16 h, 100% b): (Boc)2O, Et3N, MeOH, 50 oC, 3 d, 63%; c) NaH, DMF, TsOCH2CH2 OTs,
0 oC to 5 oC, 6 h, 46%; d) NaH, DMF, FCH2CH2Br, 0 oC to rt, 6 h, 81%; e) 6N HCl, reflux, 2 h,
46%.

Cold standard for FEMT 2 was initially carried out as shown in Scheme 2.1 from
commercially available α-methyl tyrosine 5. The attempt of Boc protection of amino
group of 5 had low yield (< 30%) and required long reaction time as shown in Table 2.1.
This might be due to steric hindrance from the α-methyl group and limited solubility of 5
in water or organic solvents [29]. Since this synthetic route is flawed with low yield (i.e.
yield of tosylate precursor and standard was no more than 2% and 10% respectively) and
long reaction time, we then developed a new strategy as demonstrated in Scheme 2.2.
Protecting the carboxylic acid group of 5 first could solve the solubility issue so
subsequent Boc protection could be achieve with shorter reaction time and higher yield.
- 35 -

Methylation of the carboxylic group gave α-methyl tyrosine methyl ester 11 in
quantitative yield. The subsequent Boc protection produced protected tyrosine 12 in good
yield. Since direct nucleophilic radiofluorination is generally a better method than
indirect labeling [30, 31], we prepared labeling precursors as protected O-tosylalkyl
tyrosine derivatives. Tosylate precursor 13 was obtained in a yield of 46% after treating
12 with ethylene glycol ditosylate and NaH in DMF. Alkylation of 12 with 1-bromo-2fluoroethane followed by deprotection in 6 N HCl, FEMT 2 was prepared with 23%
overall yield.
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I
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b,c
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15

COOMe
17

16

e
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F
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O
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COOH

d
F

O
N
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BocHN
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COOMe
19

OTs

BocHN

COOMe
18

Scheme 2.3. Synthesis of FEAT 3. Reagenet and conditions: a) (i) Zinc dust, I2, DMF, rt, 1 h; (ii)
2,5-dibromopyridine, Pd(PPh3)Cl2, 68 oC, 2 h, 73%; b) bis(pinacolato) diboron, Pd(dppf)Cl2,
KOAc, 85 oC, 4 h; c) H2O2, CH2Cl2, 0 oC to rt, 16 h, 76%; d) TsOCH2 CH2OTs, K2CO3, DMF, 70
o
C, 47%; e) FCH2 CH2Br, K2CO3, DMF, 70 o C, 2 h, 67%; f) 6 N HCl, reflux, 4 h, 75%.

For synthesis of FEAT 3, the important intermediate is Boc-L-2-azatyrosine
methyl ester 17, which was prepared following the same procedure reported by Germain
et al [32] via Negishi cross coupling using 2,5-dibromopyridine as precursor and
subsequent hydroboration-oxidation

reaction (Scheme 2.3). From this protected

azatyrosine intermediate 17, we could obtain labeling precursor 18 and FEAT 3 through
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alkylation reactions as described in FEMT synthesis with 26 % and 28 % overall yield,
respectively. We were interested in comparing the 2-azatyrosine and 3-azatyrosine
derivatives to see how the position of N atom in aromatic ring affects ligands’ activity.
However, via Negishi coupling reaction, we could not obtain the intermediate with
acceptable yield for synthesis of labeling precursor and standard of O-fluoroethyl 3azatyrosine as shown in Scheme 2.4 and Table 2.2.
a
X

OH

X

O

N

R

N

20a, X= I
20b, X= Br

21a, X= I, R = OTHP
21b, X= Br, R = OTHP
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22b, X= Br, R = OTHP
O
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c

x
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Scheme 2.4. Attempted synthesis of 3-azatyrosine derivative. Reagenet and conditions: a) PPh3,
DIAD, THF, HO(CH2)2 OTHP or HO(CH2)2F, -5oC-10 oC, 2 h; b) 21a or 21b, Pd-catalyst, DMF,
detailed condition and results as listed in Table 2.2; c) 22a or 22b, Pd(PPh3)2Cl2, DMF, rt

Table 2.2: Conditions and results of synthesis of 23 via Negishi Coupling
X

Pd Catalyst (5 mol%)

Temperature
o

Reaction time (h)

Yield %

I

Pd(PPh3)2Cl2

rt to 55 C

5

6%

I

Pd(PPh3)2Cl2

rt

19

~1%

I

Pd(dppf)Cl2

Br
Br
Br
Br

Pd(PPh3)2Cl2

28

~1%

o

rt
o

21

No product

o

o

50 C to 65 C

Pd(dppf)Cl2

50 C to 55 C

21

~1%

Pd(dppf)Cl2

o

70 C

30

5%

PEPPSI

o

30

5%

50 C
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Cold standard for FETA, 4 was prepared from Boc-L-tyrosine 25 in three steps
(Scheme 2.5) – direct alkylation on phenol, coupling reaction with 2,4,6-trimethoxy
benzylamide (Tmob-NH2) and final deprotection reaction with trifluoroacetic acid.
Tosylate precursor 30 was synthesized in a similar manner, except it required selectively
protecting the ethoxyl group on phenol with TBDMS and removing the protecting group
with TBAF after coupling reaction with Tmob-NH2. Overall yield of FETA was 34% and
of precursor 30 was 47%.
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Scheme 2.5. Synthesis of FETA 4. Reagents and conditions: a) NaH, FCH2CH2 Br, DMF, 0 oC to
rt,overnight, 84%; b): Tmob-NH2.HCl, HOBt,DIPEA, HBTU, DMF, 0 oC to rt, 2 h, 80%; c) TFA,
CH2Cl2, 4 h, 50%; d) NaH, BrCH2CH2 OTBDMS, DMF, 0 oC to rt,overnight, 90%;e) TmobNH2.HCl, HOBt,DIPEA, HBTU, DMF,0 oC to rt, 2 h, 77%;f) TBAF, THF, 1 h, 78%; g) TsCl,
Et3N, CH2Cl2, overnight, 87%.
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2.2.2 Radiolabeling of tyrosine derivatives
TsO

X
BocHN

18F

a, b

R2

O

R2

O

COR3

X

COR1

H 2N
[18F]1,

R2 =H,

R3 =

OH, X= CH
[18F]2, R2 = Me, R3 = OH, X =CH
[18F]3, R2 = H, R3 = OH, X= N
[18F]4,!R2 = H, R3 =!NH2, X= CH

31, R1= OBut, R2 =H, X= CH
13, R1 = OMe, R2 = Me, X =CH
18, R1 = OMe, R2 = H, X= N
30, R1 = NHTmob, R2 = H, X =!CH

Scheme 2.6. Radiolabeling reactions for tyrosine derivatives. Reagents and conditions: a)
[18F]KF, K[2.2.2], K2CO3, CH3CN, 90 oC, 10 min; b) deprotection as listed in Table 2.3.

Table 2.3. Deprotection reaction conditions, average decay-corrected RCY and specific
activities at end of synthesis (EOS).
Ligands

Deprotection reaction conditions	
  

18

[ F]1
[18F]2
[18F]3

RCY (%)	
  

Specific Activity (GBq/µ mol)	
  

TFA, 60 C, 10 min
1) TFA, 60 oC, 5 min;
2) 2 N NaOH, 100 o C, 10 min
6 M HCl, 120 oC, 10 min

44 ± 8
30 ± 8

32 ± 12
13 ± 3

37 ± 8

23 ± 12

o

5±2

54 ± 12

o

18

[ F]4

TFA, 60 C, 10 min

*Values are means of three to six experiments; standard deviation is given in parentheses.

All of the

18

F labeled ligands, FET ([18F]1), FEMT ([18F]2), FEAT ([18F]3), and

FETA ([18F]4), were prepared via nucleophilic substitution of tosylate with non-carrieradded [18F]KF-K[2.2.2] complex in acetonitrile, followed by deprotection (Scheme 2.6).
In general, fluorination reaction could reach completion within 10 min at 90 oC.
Deprotection reaction conditions vary as shown in Table 2.3. All ligands were purified
with semi-preparative HPLC and were prepared within 100 min in good radiochemical
purity (RCP, > 95%) determined by both analytical HPLC and TLC. Results of labeling
such as decay–corrected radiochemical yield (RCY) and specific activity were
summarized in Table 2.3. It is noteworthy to point out that two-step deprotection was
used for FEMT, first remove Boc using TFA and then cleave methyl group via reflux in
NaOH solution. We have tried to use one-step deprotection by refluxing in 6 M HCl,
- 39 -

however, even after 20 min, fluorinated intermediate still could not be fully converted to
final product FEMT. Another issue in preparation of these tyrosine derivatives is the low
yield of FETA. We observed that using TFA at 60 oC for 10 min was not sufficient to
fully remove the Tmob protecting group. But considering possible hydrolysis of FETA to
FET, we did not increase reaction temperature or time to improve the deprotection rate.

2.2.3 In vitro cell uptake studies

Figure 2.2a Uptake of new tyrosine derivatives in reference to FET ([18F]1). Maximum uptake of ligands
was normalized to FET’s highest uptake in U138-MG.
a
Experiment performed by Brain Lieberman [33].

After successfully synthesizing

18

F labeled tyrosine derivatives, we carried out

cell uptake studies as initial biological evaluation in U-138 MG human glioblastoma
cells. U-138 MG was used as positive control in uptake of FET and IMT [34, 35]. Since
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FET ([18F]1), was used as reference compound, we chose U-138 MG to establish the
standard for amino acid tracers’ uptake. The cellular uptake of

18

F labeled tyrosine

derivatives (Figure 2.2) followed the order of FET ([18F]1) > FEAT ([18F]3) > FEMT
([18F]2) ≈ FETA ([18F]4).
The uptake of the tracers depends on the ligands’ binding affinity to amino acid
transporters and their transport rate. From the uptake results, we could make some
inference about amino acid transporters substrate recognition. The low uptake of FEMT
([18F]2), the α-methyl substituted FET ([18F]1), indicates O-fluoroalkyl α-methyl tyrosine
derivatives may not be good substrates for amino acid transporters. As we know, there
are four subtypes of LATs discovered by now, designated as LAT1 to LAT4. Although
they have significant overlap of substrate selectivity, it is suggested that some amino acid
based tracers have preference towards specific subtypes of system L, in particular, FET
([18F]1) probably prefer to be transported via LAT2 [16]. It is reported that α-methyl
substitution is tolerated by LAT1 but no evidence suggest that LAT2 could accept αmethyl substitution as well,[26] this might be the reason that FEMT ([18F]2) has
significantly lower uptake than FET ([18F]1). FEAT ([18F]3), has a substituted pyridine
side chain, which reduces its lipophilicity compared to FET ([18F]1) and this potentially
leads to its low uptake into cells. FETA ([18F]4), which substitutes carboxylic acid with
amide, is a poor substrate. In agreement, tyramine, dopamine, as well as phenylalanine
methyl ester, which lack the free carboxylic acid group, are not good substrates for amino
acid transporters either.[26, 36] These results suggest that α-carboxylic acid might be
essential amino acid transporters’ substrate recognition.
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2.3 Conclusion
In summary, three new potential PET imaging agents FEMT ([18F]2), FEAT
([18F]3) and FETA ([18F]4) were synthesized, radiolabeled and evaluated via cell uptake
studies in U-138 MG. New tracers exhibited lower uptake compared to clinically utilized
FET ([18F]1). Although these ligands might not be useful imaging agents, they provided
insight for amino acid transporters’ substrate recognition patterns.

2.4 Experimental Section
2.4.1 General information
All chemicals were purchased from Aldrich Chemical (St. Louis, MO) or TCI
America (Portland, OR). The commercially available materials were used without further
purification unless otherwise indicated. 1H spectra and

13

C NMR was recorded by a

Bruker DPX spectrometer at 200 MHz and 50 MHz respectively and referenced to NMR
solvents as indicated. Chemical shifts are reported in ppm (δ), coupling constant J in Hz.
High-resolution mass spectrometry (HRMS) data were obtained with an Agilent (Santa
Clara, CA) G3250AA LC/MSD TOF system. Thin-layer chromatography (TLC) analyses
were performed using silica gel 60 F254 plates (Merck, Germany). Crude compounds
generally were purified by flash column chromatography (FC) packed with silica gel
(Aldrich). [18F]Fluoride was purchased from IBA Molecular (Somerset, NJ) as an
[18O]enriched aqueous solution of [18F]fluoride. Solid-phase extraction (SPE) cartridges
such as Sep-Pak QMA Light and Oasis HLB cartridges were purchased from Waters
(Milford, MA). High performance liquid chromatography (HPLC) was performed on an
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Agilent 1100 series system. [18F]radioactivity was measured by gamma counter (Cobra II
auto-gamma counter D5003 spectrometer, Canberra-Packard) in the 400-1600 keV
energy range. Specific activity (SA) was calculated by comparing UV peak intensity of
final products with calibration curves of corresponding non-radioactive standards of
known concentrations. Cell lines were obtained from the American Tissue Culture
Collection (ATCC) and cultured according to ATCC recommended conditions.

2.4.2 Synthesis of precursors and standards for radiolabeling

F

O
COOH
H 2N

O-Fluoroethyl-L-tyrosine (1): 1H-NMR (200MHz, Acetic acid-d4): δ = 7.24 (d,
2H, J = 8.6 Hz), 6.91 (d, 2H, J = 8.6 Hz), 4.73 (dt, 2H, J1 = 47.4 Hz, J2 = 4.0 Hz), 4.40
(dd, 1H, J1 = 7.6 Hz, J2 = 5.2 Hz), 4.22 (dt, 2H, J1 = 29.2 Hz, J2 = 4.0 Hz), 3.52-3.22 (m,
2H); 13C NMR (50MHz, Acetic acid-d4) δ =173.1, 158.2, 130.8,126.9, 115.0, 81.9 (d, J =
167.5 Hz), 67.2 (d, J = 20.0 Hz), 55.8, 35.1; HRMS calcd for C11H14FNO3 ([M+H]+)
228.1036, found 228.1265. [α]23D -3.4o (c 0.53, 6 N HCl).

HO
COOH
BocHN

2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)-2-methylpropanoic

acid

(6): 2.0 to 5.0 equivalent base was added to a suspension of α-methyl tyrosine 5 in
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dioxane/H2O (1/1), the reaction mixture was cooled to 0°C and di-tert-butyl dicarbonate
(1.5 equiv) was added and reaction mixture was kept under various temperature and time
as shown in Table 1. Upon completion, 1N KHSO4 was added to reaction mixture to
adjust pH around 2 then extract with ethyl acetate three times. Combined organic layer
was washed with brine and dried over Na2SO4. Solvent was removed under reduced
pressure. Resulting crude product was purified by FC (Acetic acid/MeOH/CH2Cl2,
0.5/4/100). 1H NMR (200MHz, MeOD-d4) δ =6.96 (d, 2H, J = 8.4 Hz), 6.67 (d, 2H, J
=8.6 Hz), 3.17 (d, 1H, J = 13.6 Hz), 3.05 (d, 1H, J = 13.6 Hz), 1.47 (s, 9H), 1.39 (s, 3H).
13

C NMR (50MHz, CDCl3) δ =177.8, 157.4, 156.7, 132.5, 128.8, 116.0, 80.5, 61.0, 41.9,

29.0, 23.8. HRMS calcd for C15H21NO5 ([M+Na]+) 318.1317, found 318.1314

HO
COOBut
BocHN

tert-butyl

2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)-2-methyl

propanoate (7): tert-butyl 2,2,2-trichloroacetimidate (473 mg, 2.16 mmol) was added to
a solution of 6 (160 mg, 0.54 mmol) in metheylene chloride (2.0 mL) and THF (0.5 mL).
Stirred at 40°C for 18 h. After reaction being quenched with NaHCO3 (150 mg, 2.4
mmol), the resulting mixture was filtered and concentrated in vacuo and resulting residue
was purified by FC (EtOAc/Hexanes, 15/85 to 25/75) to yield product as white foam. 1H
NMR (200 MHz, CDCl3) δ =7.00 (d, 2H, J = 8.4 Hz), 6.73 (d, 2H, J =8.4 Hz), 5.20 (s,
1H), 3.31 (d, 1H, J = 13.6 Hz), 3.09 (d, 1H, J = 13.6 Hz), 1.53 (s, 3H), 1.47 (s, 18H). 13C
NMR (50 MHz, CDCl3) δ = 173.2, 167.9, 155.1,154.6, 132.5, 128.2, 115.1, 82.1, 79.5,
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60.5, 40.9, 28.9, 27.2, 24.9. HRMS calcd for C19H29NO5 ([M+Na]+) 374.1943, found
374.1942.

TsO

O
COOBut
BocHN

tert-butyl

2-(tert-butoxycarbonylamino)-2-methyl-3-(4-(2(tosyloxy)ethoxy)

phenyl)propanoate (8): 7 (207 mg, 0.67mmol) was dissolved in 1mL dry DMF and
added to NaH (60% in mineral oil, 40mg, 1.0mmol) in 4mL DMF at 0°C and reaction
mixture was stirred at 0°C for 1h.1, 2-bis(tosyloxy)ethane (371 mg, 1.0 mmol) in 1mL
DMF was added and reaction continued for 5h at 0 to 5°C. After reaction, reaction
solution was diluted with 60mL EtOAc and washed with 5mL water twice and then 5mL
brine. Organic layer dried over Na2SO4 and solvent was removed under reduced pressure.
Crude mixture was purified by FC (MeOH/CH2Cl2, 0.5/100). 1H-NMR (200MHz,
CDCl3): δ = 7.82 (d, 2H, J = 8.4 Hz), 7.35 (d, 2H, J = 8.4 Hz), 7.06 (d, 2H, J = 8.6 Hz),
6.68 (d, 2H, J = 8.6 Hz), 4.36 (dd, 2H, J1 = 6.0 Hz, J2=3.5 Hz), 4.13 (dd, 2H, J1 = 5.8 Hz,
J2=3.8 Hz), 3.33 (d, 1H, J = 13.6 Hz), 3.09 (d, 1H, J = 13.6 Hz), 2.46 (s, 3H), 1.52 (s,
3H), 1.47 (s, 18H).

13

C NMR (50MHz, CDCl3) δ =173.3, 157.2, 154.5,145.1, 133.4,

131.5, 130.1, 128.3, 114.4, 82.2, 79.4, 68.4, 65.8, 60.7, 40.7, 28.7, 28.2, 24.2, 21.8.
HRMS calcd for C28H39NO8S ([M+Na]+) 570.2294, found 570.2289.
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F

O
COOH
BocHN

2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethoxy)phenyl)-2 methylpropanoic acid (9): N-Boc α-methyltyrosine (6, 127 mg, 0.43mmol) was dissolved in 1mL dry
DMF and added to NaH (60% in mineral oil, 43mg, 1.1mmol) in 2 mL DMF at 0°C and
reaction mixture was stirred at 0°C for 1 h.1-Bromo-2-fluoro ethane (108 mg, 0.86
mmol) in 0.5mL DMF was added and reaction continued for 6 h at 0 to 5°C. After
reaction, reaction solution was diluted with 60mL EtOAc and washed with 5mL water
twice and then 5mL brine. Organic layer dried over Na2SO4 and solvent was removed
under reduced pressure. Crude mixture was purified by FC (Acetic acid/EtOAc/Hexanes,
0.5/25/75). 1H-NMR (200MHz, CDCl3): δ = 10.4 (s, 1H), 7.08 (d, 2H, J = 8.6 Hz), 6.84
(d, 2H, J = 8.6 Hz), 5.11 (s, 1H), 4.75 (dt, 2H, J1 = 47.4 Hz, J2 =4.0 Hz), 4.18 (dt, 2H, J1
= 28.0 Hz, J2 =4.0 Hz), 3.24 (s, 2H), 1.54 (s, 3H) 1.47 (s, 9H).

13

C NMR (50MHz,

CDCl3) δ =180.3, 162.1, 157.1, 155.2, 131.4, 130.1, 114.2, 82.0 (d, J = 169.5 Hz), 79.5 ,
67.1 (d, J = 20.5 Hz), 60.4, 40.6, 28.4, 24.7.HRMS calcd for C17H24FNO5 ([M+Na]+)
364.1536, found 364.1539.
F

O
COOBut
BocHN

tert-butyl

2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethoxy)phenyl)-2-

methylpropanoate (10):

To solution of 9 (60 mg, 0.19 mmol) in 2 mL

CH2Cl2/cyclohexane (1:1) was added tert-butyl 2,2,2-trichloro acetimidate (166 mg, 0.78
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mmol). Stirred at 50 °C for 1 d. After being quenched with NaHCO3 (70 mg, 0.8 mmol),
the reaction was filtered and concentrated in vacuo and resulting residue was purified by
FC (EtOAc/Hexanes, 10/9) to yield product as white solid. 1H NMR (200MHz, CDCl3) δ
=7.07 (d, 2H, J = 8.6 Hz), 6.83 (d, 2H, J =8.6 Hz), 5.19 (s, 1H), 4.75 (dt, 2H, J1 = 47.2
Hz, J2 =4.2 Hz), 4.20 (dt, 2H, J1 = 27.8 Hz, J2 =4.2 Hz), 3.34 (d, 1H, J = 13.6 Hz), 3.11
(d, 1H, J = 13.6 Hz), 1.53 (s, 3H), 1.48 (s, 18H). 13C NMR (50MHz, CDCl3) δ =173.3,
157.6, 154.6, 131.5, 129.9, 114.5, 82.2, 82.1 (d, J = 169.5 Hz), 79.4, 67.4 (d, J = 21.0
Hz), 60.7, 40.8, 28.7, 28.2, 24.2. HRMS calcd for C21H32FNO5 ([M+Na]+) 420.2162,
found 420.2154.

HO
H2N

Methyl

COOMe
.HCl

2-amino-3-(4-hydroxyphenyl)-2-methylpropanoate

(11):

Thionyl

chloride (3.7 mL, 51.2 mmol) was added to a suspension of α-methyltyrosine (5, 1.00 g,
5.12 mmol) in 25 mL methanol at 0°C. The reaction mixture was refluxed overnight.
After concentrated in vacuo, 1.3 g transparent oil was obtained for use in the next step, as
product without further purification. 1H NMR (200 MHz, MeOD-d4) δ = 7.00 (d, 2H, J =
8.6 Hz), 6.77 (d, 2H, J = 8.4 Hz), 3.83 (s, 3H), 3.19 (d, 1H, J = 14.2 Hz), 3.00 (d, 1H, J =
14.2 Hz), 1.59 (s, 3H);

13

C NMR (50 MHz, MeOD-d4) δ = 172.4, 158.7, 132.4, 124.8,

117.0, 62.2, 54.0, 43.5, 22.5; HRMS calcd for C11H15NO3 ([M+H]+) 210.1130, found
210.1137.
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HO
COOMe
BocHN

Methyl 2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)-2-methylpropane
-ate or N-Boc α-methyltyrosine methyl ester (12): Triethylamine was added to a
solution of α-methyltyrosine methyl ester (11, 2.37 g, 11 mmol) in 25 mL methanol. The
reaction mixture was cooled to 0°C. Di-tert-butyl dicarbonate (2.23 g, 10.2 mmol) was
added, and stirred at 50°C for 2d. Upon completion, the combined organic layer was
washed with brine and then dried over Na2SO4. Solvent was removed under reduced
pressure. Resulting crude product was purified by FC (EtOAc/Hexanes, 15/85 to 25/75).
1

H NMR (200 MHz, CDCl3) δ =6.95 (d, 2H, J = 8.4 Hz), 6.73 (d, 2H, J = 8.6 Hz), 5.12

(s, 1H), 3.76 (s, 3H), 3.28 (d, 1H, J = 13.6 Hz), 3.11 (d, 1H, J = 13.6 Hz), 1.56 (s, 3H),
1.48 (s, 9H);

13

C NMR (50 MHz, CDCl3) δ =174.9, 155.5, 154.9, 131.2, 115.4, 79.7,

60.6, 52.6, 41.6, 28.5, 23.6; HRMS calcd for C16H23NO5 ([M+Na]+) 332.1474, found
332.1464

TsO

O
COOMe
BocHN

Methyl

2-(tert-butoxycarbonylamino)-2-methyl-3-(4-(2-(tosyloxy)ethoxy)

phenyl) propanoate (13): N-Boc α-methyltyrosine methyl ester (12, 133 mg, 0.43
mmol) was dissolved in 1 mL dry DMF and added to NaH (16 mg, 0.65 mmol) in 2 mL
DMF at 0°C. The reaction mixture was stirred at 0°C for 1h. 1, 2-bis(tosyloxy)ethane
(240 mg, 0.65 mmol) in 0.5 mL DMF was added and the reaction continued for 5h at 0 to
- 48 -

5 °C. After the reaction, the solution was diluted with 60 mL EtOAc and washed twice
with 5 mL water and then 5 mL brine. The organic layer was dried over Na2SO4 and
solvent was removed under reduced pressure. Crude mixture was purified by FC (MeOH/
CH2Cl2, 0.5/100). 1H-NMR (200 MHz, CDCl3): δ = 7.83 (d, 2H, J = 8.2 Hz), 7.35 (d, 2H,
J = 8.4 Hz), 6.97 (d, 2H, J = 8.4 Hz), 6.70 (d, 2H, J = 8.2 Hz), 5.11 (s, 1H), 4.36 (dd, 2H,
J1 = 6.0 Hz, J2=3.6 Hz), 4.13 (dd, 2H, J1 = 6.0 Hz, J2=3.8 Hz), 3.31 (d, 1H, J = 13.8 Hz),
3.12 (d, 1H, J = 13.6 Hz), 2.46 (s, 3H), 1.56 (s, 3H), 1.47 (s, 9H);

13

C NMR (50 MHz,

CDCl3) δ =174.6, 157.3, 154.5, 145.1, 133.3, 131.2, 130.0, 129.4, 128.2, 114.6, 79.7,
68.3, 65.7, 60.6, 53.6, 52.6, 41.2, 28.6, 23.8, 21.8; HRMS calcd for C28H39NO8S
([M+Na]+) 572.2294, found 572.2289.
F

O
COOMe
BocHN

Methyl 2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethoxy)phenyl)-2-methyl
propaneate (14): N-Boc α-methyltyrosine methyl ester (12, 274 mg, 0.89 mmol) was
dissolved in 1 mL dry DMF and added to NaH (34 mg, 1.33 mmol) in 4 mL DMF at 0°C.
The reaction mixture was stirred at 0°C for 1h. 1-Bromo-2- fluoroethane (223 mg, 1.77
mmol) in 1 mL DMF was added and reaction continued for 6h at 0 to 5°C. After the
reaction, the solution was diluted with 60 mL EtOAc and washed with 5 mL water twice
and then 5 mL brine. The organic layer was dried over Na2SO4 and solvent was removed
under reduced pressure. Crude mixture was purified by FC (EtOAc/Hexanes, 15/85). 1H
NMR (200 MHz, CDCl3) δ =7.01 (d, 2H, J = 8.6 Hz), 6.84 (d, 2H, J =8.6 Hz), 5.11 (s,
1H), 4.75 (dt, 2H, J1 = 47.2 Hz, J2 =4.2 Hz), 4.20 (dt, 2H, J1 = 27.8 Hz, J2 =4.2 Hz), 3.76
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(s, 3H), 3.32 (d, 1H, J = 13.8 Hz), 3.14 (d, 1H, J = 13.6 Hz), 1.56 (s, 3H), 1.48 (s, 9H);
13

C NMR (50 MHz, CDCl3) δ =174.6, 157.7, 154.6, 131.3, 129.3, 114.6, 82.1 (d, J

=169.5 Hz), 79.7, 67.3 (d, J =20.5 Hz), 60.7, 52.6, 41.3, 28.6, 23.8; HRMS calcd for
C18H26FNO5 ([M+Na]+) 378.1693, found 360.1693.
F

O
COOH
H 2N

2-amino-3-(4-(2-fluoroethoxy)phenyl)-2-methylpropanoic

acid

or

O-

Fluoroethyl α-methyl tyrosine (2): Methyl 2-(tert-butoxycarbonylamino)-3-(4-(2fluoroethoxy)phenyl) -2-methyl propanoate (14, 154 mg, 0.43 mmol) was dissolve in 7
mL 6 N HCl. The reaction mixture was stirred at reflux for 2.5 h. After evaporated to
dryness, the resulting solid was dissolved in 2 mL MeOH. The solution was adjusted to
pH ~7 with 5% NH4OH resulting a white precipitate. The suspension was left in the
refrigerator overnight and then filtered to produce O-fluoroethyl α-methyl tyrosine as a
white solid. 1H NMR (200 MHz, TFA-D+CDCl3) δ =7.11 (d, 2H, J = 7.6 Hz), 6.93 (d,
2H, J =7.4 Hz), 4.77 (dt, 2H, J1 = 47.2 Hz, J2 =4.0 Hz), 4.21 (dt, 2H, J1 = 28.0 Hz, J2
=4.0 Hz), 3.41 (d, 1H, J = 14.2 Hz), 3.16 (d, 1H, J = 14.8 Hz), 1.78 (s, 3H); 13C NMR (50
MHz, TFA-D+CDCl3) δ =175.4, 159.2, 131.4, 124.0, 116.4, 82.3 (d, J = 168.5 Hz), 67.9
(d, J = 20.0 Hz), 62.8, 41.9, 21.9; HRMS calcd for C12H16FNO3 ([M+Na]+) 264.1012,
found 264.0922.
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O

OTs

N
BocHN

COOMe

(S)-methyl 2-(tert-butoxycarbonylamino)-3-(5-(2-(tosyloxy)ethoxy)pyridin-2yl) propaneate (18): Boc-L-azatyrosine methylester

(17, 60 mg, 0.2 mmol) was

dissolved in 2 mL DMF. K2CO3 (84 mg, 0.6 mmol) and 1,2-bis(tosyloxy)ethane (112 mg,
0.3 mmol) was added sequentially. The mixture was stirred at 70 oC for 3h. After the
reaction, the mixture was diluted with 30 mL Et2O and washed with 5 mL water twice
and then 5 mL brine. The organic layer was dried over Na2SO4 and solvent was removed
under reduced pressure. Crude mixture was purified by FC (MeOH/CH2Cl2, 2:100) to
yield light yellow foam. 1H-NMR (200 MHz, CDCl3): δ = 8.10-8.08 (m, 1H), 7.82 (d,
2H, J = 7.8 Hz), 7.36 (d, 2H, J = 8.2 Hz), 7.05-7.03 (m, 2H), 5.76 (d, 1H, J = 8.0 Hz),
4.67-4.62 (m, 1H), 4.40-4.36 (m, 2H), 4.20-4.15 (m, 2H), 3.70 (s, 3H), 3.22-3.19 (m,
2H), 2.46 (s, 3H), 1.43 (s, 9H);

13

C NMR (50 MHz, CDCl3) δ = 172.4, 155.4, 153.1,

149.9, 145.1, 137.2, 132.9, 129.9, 128.0, 123.8, 122.1, 79.7, 67.8, 66.0, 53.4, 52.2, 38.5,
28.3, 21.6; HRMS calcd for C23H30N2O8S ([M+H]+) 495.1801, found 495.1787; [α]24D
+13.2o (c 0.67, CHCl3).

O

F

N
BocHN

(S)-methyl

COOMe

2-(tert-butoxycarbonylamino)-3-(5-(2-fluoroethoxy)pyridin-2-

yl)propanoate (19): Boc-L-azatyrosine methylester (17, 45 mg, 0.15 mmol) was
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dissolved in 1 mL DMF. K2CO3 (62 mg, 0.45 mmol) and 1-bromo-2-fluoroethane (38
mg, 0.3 mmol) were added sequentially. The mixture was stirred at 70oC for 2h. After the
reaction, the mixture was diluted with 30 mL Et2O and washed with 5 mL water twice
and then 5 mL brine. The organic layer was dried over Na2SO4 and solvent was removed
under reduced pressure. Crude mixture was purified by FC (MeOH/CH2Cl2, 2:100) to
yield a light yellow viscous liquid. 1H-NMR (200 MHz, CDCl3): δ = 8.24 (d, 1H, J = 2.8
Hz), 7.17 (dd, 1H, J1 = 8.4, J2= 2.8 Hz), 7.06 (d, 1H, J = 8.6 Hz), 5.79 (d, J = 7.8 Hz),
4.90-4.85 (m, 1H), 4.65-4.52 (m, 2H), 4.33-4.28(m, 1H), 4.19-4.14 (m, 1H), 3.70 (s, 3H),
3.21-3.24 (m, 2H), 1.43 (s, 9H);

13

C NMR (50 MHz, CDCl3) δ = 172.6, 155.6, 153.6,

150.0, 137.3, 124.1, 122.5, 81.8 (d, J =170.0 Hz), 79.8, 67.8 (d, J = 20.5 Hz), 53.5, 52.3,
38.7, 28.5; HRMS calcd for C16H23FN2O5 ([M+H]+) 343.1669, found 343.1680. [α]24D
+18.7o (c 0.93, CHCl3).

O
N
H 2N

F
.xHCl

COOH

(S)-2-amino-3-(5-(2-fluoroethoxy)pyridin-2-yl)propanoic acid (3): 5mL 6M
HCl was added to a 10 mL round bottom flask of (S)-methyl 2-(tertbutoxycarbonylamino)-3-(5-(2-fluoroethoxy )pyridin-2-yl)propanoate (14, 82 mg, 0.24
mmol) and refluxed for 4h. After the reaction, the mixture was diluted with 5 mL H2O.
The solution was washed with 2 mL CH2Cl2 three times. Aqueous phase was then
concentrated under reduced pressure to yield light yellow foam. 1H-NMR (200 MHz,
MeOD-d4): δ = 8.62 (d, 1H, J = 2.6 Hz), 8.28 (dd, 1H, J1 = 8.8, J2= 2.2 Hz), 8.10 (d, 1H,
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J = 9.0 Hz), 4.95-4.92 (m, 1H), 4.70-4.68 (m, 1H), 4.62-4.57 (m, 2H), 4.49-4.46 (m, 1H),
3.69 (d, 2H, J = 7.2 Hz);

13

C NMR (50 MHz, MeOD+D2O) δ = 170.0, 158.2, 144.8,

133.6, 131.3, 130.3, 82.9 (d, J =168.5 Hz), 71.0 (d, J = 19.5 Hz), 53.2, 34.3; HRMS calcd
for C10H13FN2O3 ([M+Na]+) 229.0988, found 229.0987. [α]23D +36.6o (c 0.30, 6 N HCl).

F

O
COOH
BocHN

(S)-2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethoxy)phenyl)propanoic
acid (26): N-Boc L-tyrosine (25, 563 mg, 2 mmol) was dissolved in 5 mL dry DMF and
added to NaH (95%, 127mg, 5 mmol) in 15 mL DMF at 0°C. The reaction mixture was
stirred at 0°C for 1h. 1-bromo-2-fluoroethane (504 mg, 4 mmol) was added and the
reaction continued overnight from 0°C to room temperature. After the reaction, the
solution was acidified to a pH of approximately 2 and extracted with ether (20 mL) three
times. The combined organic layer was washed with brine (10 mL), dried over MgSO4
and then concentrated in vaccuo. Crude mixture was purified by FC (AcOH/MeOH/
CH2Cl2, 0.5/3/100) to afford 26 as white foam. 1H-NMR (200 MHz, CDCl3): δ = 7.12 (d,
2H, J = 8.4 Hz), 6.86 (d, 2H, J = 8.6 Hz), 4.99 (d, 1H, J = 6.6 Hz), 4.86 (t, 1H, J = 4.2
Hz), 4.65-4.55 (m, 2H), 4.19 (dt, 2H, J1 = 27.8 Hz, J2 = 4.2 Hz), 3.19- 3.01(m, 2H), 1.42
(s, 9H); 13C NMR (50 MHz, CDCl3) δ =176.3, 157.8, 155.6, 130.7, 128.8, 115.0, 82.1 (d,
J = 169.5 Hz), 67.4 (d, J = 20.5 Hz), 54.6, 37.1, 28.4; HRMS calcd for C16H22FNO5
([M+Na]+) 350.1380, found 350.1378; [α]24D -13.1o (c 1.1, MeOH).
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F

O

O
BocHN

NHTmob

(S)-tert-butyl 3-(4-(2-fluoroethoxy)phenyl)-1-oxo-1-(2,4,6-trimethoxybenzyl
amino)propan-2-ylcarbamate (27): Diisopropylethylamine (169 mg, 1.3 mmol) was
added to a solution of propanoic acid (26, 130 mg, 0.4 mmol), 2,4,6trimethoxybenzylamine hydrochloride (102 mg, 0.44 mmol) and 1-HOBt (70 mg, 0.52
mmol) in DMF (4 mL). The solution was cooled to 0oC before HBTU (183 mg, 0.48
mmol) was added in one portion. Continue at 0oC for 30 min and then room temperature
for another 1.5 h. The reaction mixture was diluted with 15 mL EtOAc and 10 mL 10%
citric acid. The aqueous layer was extracted twice with 15 mL EtOAc and the combined
organic layer was washed with 5 mL saturated NaHCO3 and 5 mL brine. The organic
layer was dried over MgSO4 and solvent was removed under reduced pressure. Crude
mixture was purified by FC (EtOAc/Hexanes, 50/50), which produced 27 as a white
solid. 1H-NMR (200MHz, CDCl3): δ = 7.06 (d, 2H, J = 8.6 Hz), 6.73 (d, 2H, J = 8.6 Hz),
6.09 (s, 2H), 5.84 (s, 1H), 5.19 (s, 1H), 4.74 (dt, 2H, J1 = 47.4 Hz, J2= 4.2 Hz), 4.50-4.27
(m, 2H), 4.24-4.11 (m, 2H), 4.08 (t, 1H, J = 4.2 Hz), 3.82 (s, 3H), 3.76 (s, 6H), 3.06-2.84
(m, 2H), 1.40 (s, 9H); 13C NMR (50MHz, CDCl3) δ =170.2, 161.1, 159.4, 157.4, 155.4,
130.6, 129.9, 114.8, 106.7, 90.8, 82.1 (d, J = 169.5 Hz), 80.0, 67.3 (d, J = 20.5 Hz), 56.4,
55.9, 55.6, 38.6, 32.4, 28.5; HRMS calcd for C26H35FN2O7 ([M+H]+) 507.2507, found
507.2508; [α]24D -17.1o (c 0.98, CHCl3).
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F

O

O
H2N

NH2

O-fluoroethyl tyrosine amide (4): Propanylcarbamate (27, 127 mg, 0.25 mmol)
was added to 1.5 mL trifluoroacetic acid and 50 µL dimethyl sulfide, a free radical
scavenger.

The reaction mixture was stirred in room temperature for 4 h. Upon

completion, the mixture was concentrated under reduced pressure to remove TFA. The
resulting mixture was dissolved in water (5 mL) and washed with ether (5 mL). The
aqueous layer was neutralized to pH ~ 7 with 5% NH4OH and extracted with ethyl
acetate (15 mL) three times. Crude mixture was purified by preparative TLC
(Et3N/MeOH/CH2Cl2, 1/7/100), which afforded 4 as a yellowish liquid. 1H-NMR
(200MHz, MeOD-D4): δ = 7.35 (d, 2H, J = 8.6 Hz), 7.03 (d, 2H, J = 8.6 Hz), 4.85 (dt,
2H, J1 = 47.4 Hz, J2 = 4.0 Hz), 4.62 (t, 1H, J = 7.0 Hz), 4.33 (dt, 2H, J1 = 28.8 Hz, J2 =
4.0 Hz), 3.43-3.18 (m, 2H);

13

C NMR (50MHz, MeOD-d4) δ =178.0, 159.3, 131.7,

130.7, 116.1, 83.3 (d, J = 167.5 Hz), 68.8 (d, J = 20.0 Hz), 57.2, 40.9; HRMS calcd for
C11H15FN2O2 ([M+H]+) 227.1196, found 227.1213. [α]24D -14.3o (c 0.57, MeOH).

TBDMSO

O

O
BocHN

(S)-tert-butyl

NHTmob

3-(4-(2-(tert-butyldimethylsilyloxy)ethoxy)phenyl)-1-oxo-1-

(2,4,6-trimethoxybenzyl amino)propan-2-ylcarbamate (29): Diisopropylethylamine
(1.25 g, 9.7 mmol) was added to a solution of propanoic acid (28, 1.3 g, 3 mmol), 2,4,6trimethoxybenzylamine hydrochloride (772 mg, 3.3 mmol) and 1-HOBt (527 mg, 3.9
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mmol) in DMF (30 mL). The solution was cooled to 0oC before HBTU (1.35 g, 3.6
mmol) was added in one portion. Continue at 0 oC for 30 min and then room temperature
for another 1.5 h. The reaction mixture was diluted with 30 mL EtOAc and 30 mL 10%
citric acid. The aqueous layer was extracted twice with 30 mL EtOAc and the combined
organic layer was washed with 10 mL saturated NaHCO3 and 10 mL brine. The organic
layer was dried over MgSO4 and solvent was removed under reduced pressure. Crude
mixture was purified by FC (EtOAc/Hexanes, 35/65) to produce 29 as white foam. 1H
NMR (200 MHz, CDCl3) δ = 7.04 (d, 2H, J = 8.6 Hz), 6.73 (d, 2H, J =8.4 Hz), 6.09 (s,
2H), 5.88 (s, 1H), 5.19(s, 1H), 4.41-4.38 (m, 2H), 4.20-4.16(m, 1H), 3.96 (s, 4H), 3.82 (s,
3H), 3.76 (s, 6H), 3.06-2.83 (m, 2H), 1.40 (s, 9H), 0.92 (s, 9H), 0.11 (s, 6H);

13

C NMR

(50 MHz, CDCl3) δ =170.3, 161.1, 159.4, 158.0, 155.4, 130.5, 129.2, 114.7, 106.7, 90.8,
79.9, 69.5, 62.2, 56.5, 55.9, 55.5, 38.6, 32.4, 28.5, 26.1, 18.6; HRMS calcd for
C32H50N2O8Si ([M+H]+) 619.3415, found 619.3416.

TsO

O

O
BocHN

NHTmob

(S)-2-(4-(2-(tert-butoxycarbonylamino)-3-oxo-3-(2,4,6-trimethoxybenzyl
amino)propyl)phenoxy) ethyl 4-methylbenzenesulfonate (30): A THF solution of
TBAF (1 M in THF) was added to a solution of 2mL propanylcarbamate (29, 390 mg,
0.63 mmol). The reaction continued for 1 h before diluted with 10 mL water. The
aqueous solution was extracted with ether (15 mL × 3). The combined organic layer was
washed with brine and then dried over MgSO4. Solvent was removed under reduced
pressure. Resulting crude product was purified by FC (EtOAc/Hexanes, 75/25).
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Deprotection product was then dissolved in 5 mL CH2Cl2, added Et3N (200 mg, 2 mmol),
TsCl (112 mg, 0.6 mmol) and DMAP (6 mg, 0.05 mmol), reaction continued overnight.
Dilute reaction mixture with 40 mL CH2Cl2 and then washed with 5 mL saturated
NaHCO3 and 5 mL brine. Organic layer dried over MgSO4 and solvent was removed
under reduced pressure. Crude mixture was purified by FC (EtOAc/Hexanes, 60/40) to
produce 20 as yellow foam. 1H NMR (200 MHz, CDCl3) δ = 7.82 (d, 2H, J = 8.2 Hz),
7.35 (d, 2H, J = 8.0 Hz), 7.01 (d, 2H, J = 8.4 Hz), 6.60 (d, 2H, J = 8.4 Hz), 6.08 (s, 2H),
5.86 (s, 1H), 5.18 (s, 1H), 4.49-4.28 (m, 4H), 4.18-4.05 (m, 3H), 3.81 (s, 3H), 3.75 (s,
6H), 3.04-2.77 (m, 2H), 2.46 (s, 3H), 1.40 (s, 9H); 13C NMR (50 MHz, CDCl3) δ =170.2,
161.4, 159.4, 157.0, 155.4, 145.1, 133.3, 130.6, 128.2, 114.7, 106.6, 90.8, 80.0, 68.3,
65.7, 56.4, 55.9, 55.6, 38.6, 32.4, 28.5, 21.8; HRMS calcd for C33H42N2O10S ([M+Na]+)
681.2458, found 681.2463; [α]24D -13.4o (c 1.05, CHCl3).

2.4.3 Radiochemistry
In general, [18F]Fluoride was passed through a Sep-Pak light QMA cartridge
(Waters, preconditioned with 10 mL 1 N NaHCO3 , 10 mL water and dried with N2). The
18

F activity was eluted with 1.1 mL Kryptofix 222 K[2.2.2] /K2CO3/CH3CN/H2O solution

(11 mg/2 mg/ 0.93 mL/0.17 mL), azeotropically dried twice under N2 at 110oC. Then 5
mg precursor in 1 mL anhydrous CH3CN was added into

18

F. Fluorination reaction

continued for 10 min at 90oC. Chemical, radiochemical purity and specific activity of
radioligands were analyzed with analytical

HPLC and TLC. TLC system:

NH4OH/MeOH/ CH2Cl2, 1/6/14, FET Rf is 0.3, FEMT Rf is 0.4, FETA is 0.6. TLC
system: NH4OH/ MeOH/ CH2Cl2, 1/10/10, FEAT Rf is 0.4. Semi-Preparative HPLC was
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carried out on a column (Phenomenex Gemini C18 semi-preparative column, 10 × 250
mm, 5 µm). Radiochemical purity was determined by analytical HPLC (Phenomenex
Gemini C18 analytical column, 4.6 ×250 mm, 5 µm, UV detector set at 275 nm) and
TLC. Three solvent systems were used in analytical HPLC: A: ethanol/0.1 % formic acid,
10/90 (for FET and FEMT) or 2/98 (FEAT), flow rate 1mL/min; B: Gradient: 0-2 min:
100% 10mM ammonium formate buffer (AFB); 2-5min: ACN: AFB (70:30); 5-10 min:
100% ACN; 10-15% 100% AFB, flow rate 1mL/min; C: MeOH/0.1% NH3, 40/60,
1mL/min. For analytic HPLC solvent system A (ethanol/ 0.1% formic acid, 10/98 for
FET/ FEMT and 2/98 for FEAT), retention time was 5.8 min for FET, 7.2min for FEMT
and 5.5 min for FEAT respectively. For solvent system B, retention time was 7.3 min for
FET, 7.0 min for FEMT, 7.6 min for FEAT and 7.8 min for FETA respectively. With
solvent system C, retention time was 5.2 min for FETA. Details regarding purification
and deprotection reactions were described in the following paragraphs:
FET ([18F]1): After fluorination, the reaction mixture was injected to semipreparative HPLC, eluent MeOH/H2O (80:20), flow rate 3 mL/min. Radioactive peak
between 10.5 min to 12 min was collected and then diluted with 20 mL water, loaded on
HLB oasis cartridge (preconditioned with 1 mL ethanol and 5 mL water) and then eluted
with 1mL ethanol. Solvent was removed under N2, and then 0.25 mL TFA was added,
and heated at 60oC for 10 min. TFA was removed with a N2 flow, and then 1 mL water
was added to produce the final product.
FEMT ([18F]2): After fluorination, the reaction mixture was diluted with 10 mL
water, loaded on an Oasis HLB cartridge (preconditioned with 1 mL ethanol and 5 mL
water), washed twice with 2 mL water, eluted with 1mL CH2Cl2. Dry CH2Cl2 under a N2
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flow, and 0.5 mL TFA was added to the reaction mixture. The reaction continued at
60oC for 5 min. TFA was blow dried, and then 0.5 mL 2N NaOH was added, and
refluxed at 100oC for 10 min. The reaction mixture was neutralized with 2N HCl and
then ~0.5mL PBS buffer was added, and loaded on a semi-preparative HPLC
(ethanol/H2O, 10/90, flow rate 3.5 mL/min). Fraction containing FEMT (between 12 to
13 min) was collected.
FEAT ([18F]3): After fluorination, the reaction mixture was injected into a semipreparative HPLC (MeOH/H2O, 65/35, flow rate 3mL/min), and a radioactive peak
between 9.5 to 11 min was collected. Diluted with 20 mL water then loaded on an oasis
HLB cartridge and eluted with 1mL ethanol. The solution was added to 0.5 mL 6M HCl,
refluxed at 120oC for 10 min, neutralized with 2 N NaOH, and added to PBS buffer to
adjust pH ~6.
FETA ([18F]4): After fluorination, the reaction mixture was diluted with 10 mL
water, loaded on an Oasis HLB cartridge (preconditioned with 1 mL ethanol and 5 mL
water), washed twice with 2 mL water, and eluted with 1mL ethanol. Ethanol was dried
under a N2 flow, and 0.25 mL TFA was added to the reaction mixture. The reaction
continued at 60oC for 10 min. TFA was blow dried and then 1 mL water was added and
loaded on a semi-preparative HPLC (methanol/0.1% NH3, 4/6, flow rate 3 mL/min).
Fraction containing FEMT (between 11 to 13 min) was collected, diluted with 20 mL
water, loaded on a HLB cartridge and eluted with 1mL ethanol. Ethanol was removed
under N2 and final product was dissolved in 1 mL water.
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2.4.4 In vitro cell studies
Cell culture: U-138 MG in Eagle’s Minimum Essen-tial Medium (EMEM),
supplemented with 10% Fetal Bovine Serum (FBS) and 1% streptomycin. Cells were
incubated at 37oC under 5% CO2 and were subcultured by trypsinization using 0.25%
trypsin-EDTA. Cell uptake studies: cells were seeded at 2 × 105 cells/well in 12 well
tissue culture plates. After 24 h of incubation at 37°C, cells formed monolayer and
reached confluence. Cells were washed three times with warmed phosphate-buffered
saline (PBS) solution and were incubated with 1 mL of PBS containing approximately
0.5 MBq (14 µCi) of ligands. Uptake experiments were run for 5, 30, 60 and 120 min at
37°C. After incubation, PBS was quickly removed, and the cells were washed three times
with cold PBS (w/o Ca++ and Mg++) and then lysed with 350 µL 1 N NaOH. Transfer
resulting solution to test tubes for radioactivity measurement. The uptake results were
normalized to protein content and to the total activity administered. Results are expressed
as the percentage of radioactivity accumulated per 100 µg protein.
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Chapter 3

Synthesis, uptake mechanism characterization and
biological evaluation of 18F labeled fluoroalkyl
L-phenylalanine analogs as potential tumor imaging

agents for PET
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3.1 Introduction
Malignant tumors can be detected by imaging their increased metabolic rates for
glucose, lipids and amino acids [1]. One interesting metabolic process as a target for
metabolic tumor imaging is increased protein metabolism in proliferating cancer cells.
Avid uptake of amino acids is a normal feature of rapidly proliferating cells [2]. A
number of radiolabeled amino acids (Figure 3.1) were developed and have established
role in clinical applications, especially in brain tumor imaging [3, 4]. Amino acid based
tracers could overcome certain limitations of most commonly used 2-[18F]fluoro-2deoxy-D-glucose (FDG), namely high accumulation in inflammatory tissues and high
uptake in normal brain tissues [4].
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Figure 3.1. Some clinically utilized amino acid based tracers

Uncontrolled and accelerated growth of cancer cells lead to elevated rate of
protein synthesis and increased uptake of amino acids as energy source as well as carbon
and nitrogen source in the synthesis of nucleotides, amino sugars et al [5]. Some natural
amino acid based tracers such as [11C]methionine (MET) and [11C]tyrosine (TYR), their
uptake reflects transport, protein synthesis and non-protein metabolic pathways such as
transamination and transmethylation, which makes imaging kinetic analysis difficult [6-
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8]. While uptake of non-natural amino acids such as O-(2-[18F]fluoroethyl)-L-tyrosine
(FET, [18F]1) [9], 3-[18F]fluoro-α-methyl-L-tyrosine (FMT) [10], anti-1-amino-3[18F]fluoro-cyclobutyl-1-carboxylic acid (FACBC)

[11], 3-[123I]-α-methyl-L-tyrosine

(IMT) [12] represents mainly transport activity but not protein synthesis. It appears that
their differences in protein metabolism do not translate into difference in clinical
applicability[3]. Moreover,

18

F (t1/2 = 109.8 min) and

123

I (t1/2 = 13.2 h) labeled non-

natural amino acid derivatives have advantage of longer half-life than

11

C (t1/2 = 20.2

min) and are generally more stable in vivo which simplifies image analysis [3, 4, 13]. For
these reason, non-natural amino acids have been a main focus in current development of
amino acid tracers [3, 14, 15].
Amino acids are taken up into cells mainly through specific membrane associated
carrier proteins. Increased uptake of amino acids is mediated through increased
expression and activity of amino acid transporters. Amino acid transporters identified so
far are solute carrier transporters (SLC), which are classified into a number of transporter
systems based on their sodium dependence, substrate specificity, kinetics, regulatory
properties and sensitivity to pH and specific inhibitors [16]. Most commonly existing
amino acid transporter systems in mammalian cells responsible for transporting neutral
amino acids are system A (alanine preferring), ASC (alanine-serine-cystine preferring)
and system L (leucine preferring) [17]. Sodium-independent amino acid transport system
L (LATs), which is a major route for transporting large branched and aromatic amino
acids has attracted special interest [18]. Studies demonstrated that system L is a
promising target for developing PET tumor imaging agents [3, 4, 19]. The broad substrate
selectivity of LATs enables it to transport amino acid-related compounds. A number of
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substrates of LATs, such as MET, FET, FACBC, IMT, are clinically utilized for imaging
brain cancer, head and neck cancer, lung cancer and prostate cancer et al [3, 4, 15].
System L is commonly upregulated in many tumors and correlated with tumor growth
and prognosis [19-21]. There are four subtypes of LATs identified and characterized in
molecular level, designated LAT1 to LAT4 [22]. In particular, LAT1 is most studied.
LAT1 is primarily expressed in brain, placenta and tumors and closely correlated with
angiogenesis [23], cell proliferation [23] and prognosis of patients with astrocytoma [24],
non-small cell lung cancer (NSCLC) [25] and prostate cancer [26].
Phenylalanine and tyrosine derivatives, which are primarily LATs substrate, have
proven to be useful tumor imaging agents [3, 4]. In particular, FET ([18F]1) is one of the
first 18F labeled amino acid tracers that could be prepared in large quantity for clinical use
and satellite distribution similar to FDG [27]. FET is useful for detecting brain tumors
and head and neck squamous carcinoma, but its applications in peripheral tumors are
somewhat limited [28, 29]. Another clinically utilized system L substrate p-[123I]iodo-Lphenylalanine (IPA) demonstrated potential for imaging brain tumor as well [30]. This
led us to develop its fluoroalkyl derivatives, which are also structural analogs of FET.
Our goal is to develop new amino acid tracers with improved in vivo pharmacokinetics
than FET, which could lead to a higher tumor uptake and/or lower urinary excretion that
may be beneficial for imaging tumors in urinary tract such as prostate cancer, urinary
bladder carcinomas and cervical cancer [31, 32]. Eliminating oxygen to form direct
linkage of fluoroalkyl chain to phenyl ring provides a way to alter ligands’ lipophilicity
as well as to reduce length of side chain. In this study, we describe the synthesis,
radiolabeling and biological evaluation of two new phenylalanine derivatives, p-(2-
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[18F]fluoroethyl)-L-phenylalanine

[18F]2)

(FEP,

p-(3-[18F]fluoropropyl)-L-

and

phenylalanine (FPP, [18F]3) (Figure 3.2). Clinically utilized FET ([18F]1) was used as
reference in biological evaluation of new ligands.
COOH

COOH
18F

NH2

18F

NH2
[18F]3

[18F]2

FPP

FEP

Figure 3.2. Chemical structures of new phenylalanine derivatives

3.2 Results and Discussion
3.2.1 Synthesis of precursors and authentic standards
COOBut

COOBut

a

NH2

HO

COOBut

b

NHBoc

HO

4

6

5
COOBut

COOBut

d

c
NHBoc
n

HO

COOBut
NHBoc
n
n = 1, 9a
n = 2, 9b

e

NHBoc

n

n = 0, 7a
n = 1, 7b

TsO

NHBoc

TfO

n = 1, 8a
n = 2, 8b
COOBut

f
F

COOH

g

NHBoc
n

F
n = 1, 10a
n = 2, 10b

NH2

n
n = 1, 2
n = 2, 3

Scheme 3.1. Synthesis precursors and standards 2 and 3 for radiolabeling. Reagents and
Conditions: a) (Boc)2O, NaHCO3, MeOH, H2 O, rt, 89%; b) 2. Tf2 O, pyridine, CH2Cl2, 0oC, 93%;
c) Tributyl vinyltin or tributyl allyltin, LiCl, Pd(PPh3)2 Cl2, DMF, 70oC, 92% (n = 0) or 95% (n =
1); d) 9-BBN, THF, NaOH, H2 O2, 86% (n = 1) or 88% (n = 2); e) TsCl, Et3N, CH2 Cl2, 92% (n =
1) or 75% (n = 2); f) i. NaI, acetone, reflux; ii. AgF, CH3CN, 50% (n = 1) or 58% (n = 2); g)
TFA, CH2Cl2, 81% (n = 1) or 64% (n = 2).
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An efficient synthesis of fluoroalkyl phenylalanine derivatives 2 and 3 was
carried out as shown in Scheme 3.1. The tosylate precursors 9a and 9b for labeling could
be prepared in five steps in an overall yield of 60 and 52% respectively starting from
commercially available L-tyrosine tert-butyl ester. Standard Boc protection of amine
group and then triflation of phenol group on protected tyrosine 5 afforded triflate 6 in
83% yield. Triflate 6 then underwent Stille cross-coupling reaction with vinyl or allyl
tributylstanne and Pd catalyst Pd(PPh3)2Cl2 in anhydrous DMF at 70 oC for 1 h to yield
corresponding alkenes. Hydroboration alkenes 7a or 7b with 9-BBN and subsequent
oxidation with sodium peroxide afforded aliphatic alcohol 8a and 8b in 86 to 88% yield.
We chose 9-BBN as hydroboration reagent because of its high regio-selectivity in
comparison to BH3 reagent, initial reaction with BH3⋅THF had low yield (< 20%).
Tosylation of the alcohol compounds afforded labeling precursors in 75 to 92% yield.
Initially we tried to use diethylaminosulfur trifluoride (DAST) to covert aliphalic alcohol
8a directly to fluoride 10a, however under this reaction condition, it is difficult to obtain
chemically

pure

product.

In

addition,

commonly

used

fluorination

reagent

tetrabutylammonium fluoride (TBAF) might cause isomerization resulting fluorinated
product in racemic form, so here we choose to adapt mild fluorination condition in the
neutral solution. After a two-step fluorination – tosylate 9a or 9b was first convert to
iodide by refluxing with sodium iodide in acetone and then fluorinated by reacting with
silver fluoride, and deprotection with TFA, the standard 2 and 3 were obtained in an
overall yield of 24% and 19% respectively. The enantiomeric purity of precursors and
standards for radiolabeling is >95% analyzed by chiral HPLC.
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3.2.2 Radiosynthesis of phenylalanine derivatives
Preparation of FEP ([18F]2) and FPP ([18F]3) was carried out via a two-step
reaction as shown in Scheme 3.2. First step was no-carrier-added (NCA) nucleophilic
fluorination with dried TBA18F and TBAHCO3 in acetonitrile. Intermediate [18F]10a or
[18F]10b was then subjected to semi-preparative HPLC purification and HLB oasis solid
18

phase extraction to eliminate unreacted

F fluoride and other by-products. Second step

was to remove protecting groups using TFA at 60 oC. The results of labeling reactions
were summarized in Table 3.1. Enantiomerically pure [18F]2 and [18F]3 could be prepared
in 90 min with high radio purity (> 95% as measured by analytical HPLC and TLC),
moderate to good radiochemical yield (11 to 37%) and high specific activity (21 to 69
GBq/µmol) at the end of synthesis.
COOBut
TsO

NHBoc

n

COOBut

TBA18F, ACN
18F

80 oC, 5 min

NHBoc

n = 1, [18F]10a
n = 2, [18F]10b

n = 1, 9a
n = 2, 9b
COOH

TFA
60 oC, 10 min

n

18F

NH2

n

n = 1, [18F]2
n = 2, [18F]3

Scheme 3.2. Radiolabeling of FEP ([18F]2) and FPP ([18F]3)

Table 3.1. Overall synthesis time, decay-corrected RCY, radiochemical purity (RCP),
enantiomeric purity and specific activity (EOS) *
Ligands

Synthesis time
RCY (%)
(min)
[18F]2
75–82
27–37
[18F]3
78–90
11–23
*Data obtained from two to six experiments

RCP (%)
> 95
> 95
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Enantiomeric
Purity (%)
> 95
> 95

Specific activity
(GBq/ µmol)
31–69
21–25

3.2.3 Cell uptake studies
At first, we compared the time dependent uptake of new ligands FEP ([18F]2) and
FPP ([18F]3) to clinically utilized FET ([18F]1) in 9L gliosarcoma cells (Figure 3.3).
Uptake of tracers was measured at selected time points up to 2 h. Three ligands
demonstrated very similar kinetics, reaching maximum uptake within 60 min and then
washed out. The uptake follows order FEP ([18F]2)> FET ([18F]1) ≈ FPP ([18F]3). The
maximum uptake of FEP is about 1.4 fold of FET. In vitro uptake studies showed FEP
had a high accumulation and good retention in 9L glioma cells. The uptake results
indicate that shorter side chain length may be more desirable for aromatic amino acid
tracers. This agrees with the results reported by Tsukada et al, they found the shorter 18Ffluoroalkyl chain length L-tyrosine provided a better tumor-to-blood ratio [33].

Figure 3.3. Time course of uptake of FET ([18F]1), FEP ([18F]2) and FPP ([18F]3) in 9L glioma cells. The
uptake value was represented as % uptake/100 ug protein, mean ± SD (n = 3).
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3.2.4 Uptake mechanism studies of FEP
Uptake of amino acid based tracers depends on a group of amino acid transport
systems, which often have substantial overlap in substrate selectivity and thus a single
radiolabeled amino acid can be substrate for multiple amino acid transport systems. We
are interested in characterizing the uptake mechanism of FEP ([18F]2) into tumor cells. To
achieve this goal, we conducted competitive uptake inhibition studies using inhibitors
specific for system A, ASC and L, given that transport of neutral amino acids into
mammalian cells is predominantly via these systems [21]. The uptake of FEP ([18F]2)
was measure in absence of inhibitors as well as in the presence of concentration from 0.5
to 5 mM of N-methyl-α-aminoisobutyric acid (MeAIB), L-alanine (L-Ala), L-serine(LSer), 2-amino-bicylo[2.2.1]heptane-2-carboxylic acid (BCH), D-methionine and N-Ethyl
maleimide (NEM). The specificity and structure of the inhibitors are listed in Table 3.2.
Table 3.2 Inhibitors and their specificity towards amino acid transport systems
Inhibitors

Structure

Specificity

O

System A

MeAIB

OH
HN

L-Ser

COOH

HO

NH2
COOH

L-Ala

NH2

BCH

COOH

System ASC,
ASC, A, LAT2
System L, B0, B0, +

NH2

D-Met

COOH

S

LAT1

NH2
NEM

O
N
O
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LAT2, LAT3, LAT4

MeAIB is selective inhibitor of system A while L-Ala and L-Ser are inhibitors of
system ASC. BCH is primarily an inhibitor for sodium independent system L but it is
also an inhibitor for sodium dependent system B0 and B0,

+

[17]. To measure the

contribution from sodium dependent transport systems, we carried out sodium
dependence studies comparing uptake in sodium-free buffer to uptake in PBS. To further
explore the preference of FEP towards the subtypes of LATs, we carried out competitive
inhibition studies using D-Met, specific inhibitor for LAT1 and N-ethylmaleimide
(NEM), inhibitor for other subtypes LAT2 to LAT4 [22, 34].

Figure 3.4. Summary of uptake characterization studies of FEP ([18F]2) in 9L gliomas. Results were
normalized to uptake of [18F]2 in PBS solution at 30 min. Data are expressed as mean ± SD (n = 3)

The studies were performed with a 30 min incubation time and the results were
normalized to uptake of FEP in phosphate buffer solution (PBS) in absence of inhibitors
as summarized in Figure 3.4. Uptake of FEP ([18F]2) is sodium independent since
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replacing Na+ with choline showed no difference. The effect of inhibition is
concentration dependent. Uptake of FEP is most sensitive to inhibitor of LATs. 5 mM
BCH can inhibit more than 98% of uptake. On the contrast, no inhibition was observed
using MeAIB, which indicates system A has no contribution in uptake of FEP. Inhibition
of ASC via L-Ala or L-Ser has some effect but not as significant as system L, maximum
inhibition at 5 mM is about 90%. The results demonstrated that FEP ([18F]2) was
selective substrate for sodium independent transporter system L. Futhermore, LAT1
specific inhibitor D-Met has very similar effect as BCH. The impact of NEM on the
uptake is much less compared to D-Met, the maximum inhibition at 5 mM is ~30%, this
suggests uptake of FEP may prefer LAT1 in comparison to other subtypes of LATs. It is
an interesting difference in comparison to previously reported FET ([18F]1), which is
suggested to be selectively transported via LAT2. [27] There is some advantage targeting
LAT1 because it plays a critical role in cell growth and proliferation and shows increased
transport activity in many malignant tumors [19, 20]. LAT1 expression is rarely detected
in nontumor areas, in contrast, LAT2 is more ubiquitously expressed and has a high level
of expression in small intestine, kidney, placenta, as well as tissues rich in (re)absorbing
epithelia [35]. Some cancer cells such as C6 rat glioma, HeLa cervix carcinoma cells and
R1M rhabdomyosarcoma have high expression of LAT1 but showed no upregulation of
LAT2. [36, 37] In such cancer cells lack of expression of LAT2, FEP ([18F]2) might have
advantage over FET ([18F]1). Further investigations are needed to confirm the amino acid
transport systems involved in the uptake process.
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3.2.5 Biodistribution studies of FEP
From in vitro studies results, FEP seemed to be a potential tracer that worth
further investigations, so in vivo evaluations were conducted. The in vivo biodistribution
studies were carried out in fisher rats bearing 9L tumor model, which is a wellestablished animal model mimicking clinical glioblastoma multiform and a number of
amino acid based tracers used this model for biological evaluations [11, 38]. The
distribution of radioactivity in selective peripheral tissues and organs and the regional
radioactivity distribution in rat brain at 30 min and 60 min after injection of FEP were
shown in Table 3.3.
Table 3.3a. Biodistribution of FEP in Fisher rats with 9L xenograft. After single
intravenous injection, results reprented as % ID/g, mean ± SD (six rats per time point)
Organs

30 min

60 min

Blood

0.73 ± 0.08

0.65 ± 0.05

Heart

0.70 ± 0.07

0.63 ± 0.05

Muscle

0.58 ± 0.05

0.62 ± 0.05

Lung

0.68 ± 0.08

0.61 ± 0.05

Kidney

0.72 ± 0.05

0.63 ± 0.05

Pancreas

2.66 ± 0.20

2.45 ± 0.27

Spleen

0.75 ± 0.06

0.69 ± 0.05

Liver

0.71 ± 0.07

0.63 ± 0.05

Skin

0.57 ± 0.07

0.60 ± 0.09

Brain

0.53 ± 0.03

0.52 ± 0.05

Bone

0.41 ± 0.03

0.41 ± 0.04

0.82 ± 0.06

0.90 ± 0.20

Tumor/Brain

1.55

1.73

Tumor/Muscle

1.41

1.45

Tumor

a

b

Experiment carried out by Brian Lieberman [39]
Tumor n = 5 per time point.

b

The results showed FEP had higher accumulation in 9L tumor compared to
surrounding organs and tissues. The tumor to brain and tumor to muscle ratio increased
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slightly from 30 to 60 min (from 1.55 to 1.73). Tumor to blood ratio increases from 1.12
at 30 min to 1.38 at 60 min. The highest uptake was found in the pancreas, accumulation
in other organs is lower than that in tumor. Bone uptake is not significant, which
indicates that FEP ([18F]2) is metabolically stable. Similar to FET ([18F]1) [38], FEP
([18F]2) had high uptake in pancreases. This is typical for labeled amino acid analog in
rodents, which might due to high protein turnover in pancreas. Tumor uptake, bone
uptake and tumor to muscle ratio is comparable to reported FET results in the same rat
tumor model, but FEP seems to have slightly higher normal brain uptake compared with
FET resulting lower tumor to brain ratio [38].

3.2.6 Small animal imaging studies

Figure 3.5a. Small animal PET images of FEP ([18F]2, A) and FET ([18F]1,B) in tumor bearing rats. Colorcoded PET images from summed 2 h data in transverse, coronal and sagital view from left to right followed
injection of FEP and FET are shown. The arrowhead points to the 9L tumor.
a
Experiment carried out by Brian Lieberman [39]
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Finally, the in vivo tumor imaging in the rats bearing 9L model was examined.
Small animal PET imaging studies in living rats were performed and time-activity curves
were generated by drawing region of interest to assess the kinetics of FEP ([18F]2) in
comparison to FET ([18F]1). FET and FEP exhibited very similar results as shown in
Figure 3.5, a summed 2 h image. Tracers kinetics were similar as demonstrated in Time
activity curve in Figure 3.6. Both tracers have higher accumulations in tumors than
surrounding background. After 20 min of intravenous injection of FEP, radioactivity in
heart and muscle reached a plateau (Figure 3.6a). FEP had prolonged accumulation in 9L
tumors with a slow steadily increase in 2 h imaging period. High urinary excretion was
observed for both tracers, which is typical for tyrosine and phenylalanine analogs. Tumor
to muscle ratio of these two ligands is comparable, which rapidly reached a plateau
within 20 min (as shown in Figure 3.7). Imaging results indicate FEP ([18F]2) is
compared to FET ([18F]1), both are suitable for brain tumor imaging.

Figure 3.6a: Time-activity curve after injection of FEP ([18F]2) (a) and FET ([18F]1) in the rats (b)
a
Experiment carried out by Brian Lieberman [39]
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Figure 3.7 Comparison of FEP ([18F]2) and FET ([18F]1) tumor to muscle (T/M) ration.

3.3 Materials and methods
3.3.1. General
In additional to what described in Chapter two, section 2.4.1, the animal
experiments were carried out in compliance with ethics and animal welfare according to
regulation requirements.

3.3.2. Synthesis of precursors and authentic standards for radiotracers
COOBut
HO

NHBoc

3.3.2.1 (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)propanoate (5)
L-tyrosine tert-butyl ester (4, 949 mg, 4 mmol) was added to a round-bottom flask
and dissolved in 40 mL MeOH/H2O (2:1). To this mixture was added NaHCO3 (1.008 g,
12 mmol) followed by Boc2O (1.31 g, 6 mmol). The reaction mixture was allowed to stir
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for 4 h until completion as determined by TLC analysis (MeOH/CH2Cl2, 5/100). Upon
completion, the mixture was concentrated under reduced pressure to remove methanol
and then resulting solution diluted with water and extracted with EtOAc. Combined
organic layer washed with brine and dried over Na2SO4, then concentrated under reduced
pressure and purified by FC (MeOH/CH2Cl2, 5/100) to afford the product as white foam.
1

H NMR (200 MHz, CDCl3) δ = 7.04 (d, 2H, J = 8.6 Hz), 6.75 (d, 2H, J = 8.6 Hz), 4.98

(d, 1H, J = 8.0 Hz), 4.43-4.36 (m, 1H), 2.98 (d, 2H, J = 5.8 Hz), 1.43 (s, 18H). 13C NMR
(50 MHz, CDCl3) δ = 171.5, 155.6, 155.4, 130.8, 128.0, 115.6, 82.4, 55.4, 37.9, 28.5,
28.2. HRMS calcd for C18H27NO5 ([M+Na]+) 360.1997, found 360.1986. [α]24D +39.3o (c
0.29, CHCl3).
COOBut
TfO

3.3.2.2.

NHBoc

(S)-tert-butyl2-(tert-butoxycarbonylamino)-3-(4-(trifluoromethylsulfonyloxy)

phenyl)propanoate (6)
5 (515 mg, 1.53 mmol) and pyridine (302 mg, 3.82 mmol) in CH2Cl2 at 0 oC was
added Tf2O (385 µL, 2.29 mmol) dropwise. Reaction stirred for 45 min at 0 oC. Then
dilute with CH2Cl2 (50 mL), washed with 1 N NaOH (5 mL), 10% citric acid (5 mL) and
brine (10 mL). The organic layer was dried over MgSO4, filtered and concentrated in
vacuo. The residue was purified by FC (EtOAC/Hexanes, 1/9) to give 5 as light yellow
liquid. 1H NMR (200 MHz, CDCl3) δ = 7.28 (d, 2H, J = 8.8 Hz), 7.19 (d, 2H, J = 9.0 Hz),
5.07 (d, 1H, J = 7.2 Hz), 4.53-4.37 (m, 1H), 3.07 (d, 2H, J = 6.0 Hz), 1.42 (s, 9H), 1.38
(s, 9H). 13C NMR (50 MHz, MeOD) δ = 172.7, 157.9, 150.1, 140.0, 132.7, 122.4, 83.1,
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80.8, 57.02, 38.4, 28.8, 28.3. HRMS calcd for C19H26F3NO7S ([M+Na]+) 492.1280,
found 492.1299. [α]24D +28.7o (c 1.0, CHCl3).
3.3.2.3. Stille cross-coupling for synthesis of 7a and 7b
Triflate 6 (1.0 equiv) in DMF was added to flamed dried flask containing LiCl
(3.0 eqiv), Pd(PPh3)2Cl2 (0.05 equiv), tributyl(vinyl)tin or tributyl(allyl)tin (1.3 equiv) in
DMF. Reaction mixture was degassed for 5 min and then heated at 70 oC for 90 min at
which point TLC indicated completion of reaction. The mixture was cooled to room
temperature, diluted with water and then extracted three times with ether, combined
organic layer was washed with brine, dried over MgSO4, filtered and concentrated. Crude
products were purified by FC (EtOAc/Hexanes, 5/95) to afford products as white solids.
COOBut
NHBoc

3.3.2.3.1 (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-vinylphenyl)propanoate (7a)
Yield: 92%. 1H NMR (200 MHz, CDCl3) δ = 7.34 (d, 2H, J = 8.0 Hz), 7.14 (d,
2H, J = 8.2 Hz), 6.70 (dd, 1H, J = 17.6, 10.8 Hz), 5.73 (d, 1H, J = 17.6 Hz), 5.23 (d, 1H,
J =10.8 Hz), 4.99 (d, 1H, J = 7.8 Hz), 4.54-4.37 (m, 1H), 3.05 (d, 2H, J = 6.0 Hz), 1.43
(s, 18H). 13C NMR (50 MHz, CDCl3) δ = 171.1, 155.3, 136.8, 136.5, 136.3, 129.9, 126.4,
113.7, 82.3, 79.9, 55.1, 38.5, 28.5, 28.2. HRMS calcd for C20H29NO4 ([M+Na]+)
370.1994, found 370.2001. [α]24D +42.7o (c 1.13, CHCl3).
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COOBut
NHBoc

3.3.2.3.2 (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-allylphenyl)propanoate (7b)
Yield: 95%. 1H NMR (200 MHz, CDCl3) δ = 7.20-7.10 (m, 4H), 6.06-5.85 (m,
1H), 5.10 (d, 1H, J = 5.8 Hz), 5.05-4.96 (m, 2H), 4.54-4.37 (m, 1H), 3.36 (d, 2H, J = 6.8
Hz) 3.02 (d, 2H, J = 6.0 Hz), 1.43 (s, 18H). 13C NMR (50 MHz, CDCl3) δ =171.1, 155.2,
138.7, 137.6, 134.2, 129.7, 128.7, 115.8, 82.0, 79.7, 55.1, 40.0, 38.3, 28.5, 28.1. HRMS
calcd for C21H31NO4 ([M+Na]+) 384.2151, found 384.2133. [α]24D +33.7o (c 0.47,
CHCl3).
3.3.2.4. Hydroboration-oxidation reaction for synthesis of 8a and 8b
To solution of corresponding alkene 7a or 7b in THF, 0.5 M 9-BBN in THF (3.0
equiv) was added dropwise, stirred for 3 h at room temperature. The solution was then
cooled to 0 oC , 3 N NaOH solution was added followed by H2O2 (30% in H2O). Reaction
continued at room temperature for additional 3 h, the biphasic mixture was treated with
saturated Na2S2O3 and extract three times with EtOAc, combined organic extracts were
washed with brine, dried over MgSO4, filtered and concentrated. The crude mixtures
were purified with FC (EtOAc/Hexanes, 3/7) to give products as clear viscous liquids.
COOBut
NHBoc

HO

3.3.2.4.1.

(S)-tert-butyl

2-(tert-butoxycarbonylamino)-3-(4-(2-hydroxyethyl)phenyl)

propanoate (8a)
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Yield: 86%. 1H NMR (200 MHz, CDCl3) δ = 7.20-7.08 (m, 4H), 4.99 (d, 1H, J =
6.8 Hz), 4.52-4.37 (m, 1H), 3,85 (t, 2H, J = 6.6 Hz), 2.98 (d, 2H, J = 5.8 Hz), 2.85 (t, 2H,
J = 6.6 Hz), 1.42 (s, 18H).

13

C NMR (50 MHz, CDCl3) δ = 171.1, 155.2, 137.3, 134.4,

129.7, 129.0, 82.0, 79.7, 63.6, 55.0, 38.9, 38.2, 28.3, 28.0. HRMS calcd for C20H31NO5
([M+H]+) 366.2280, found 366.2281. [α]21D +41.4o (c 0.75, CHCl3).
COOBut
HO

NHBoc

3.3.2.4.2. (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-hydroxypropyl)phenyl)
propanoate (8b)
Yield: 88%. 1H NMR (200 MHz, CDCl3) δ = 7.15-7.06 (m, 4H), 5.00 (d, 1H, J =
7.8 Hz), 4.49-4.37 (m, 1H), 3.67 (t, 2H, J = 6.4 Hz), 3.01 (d, 2H, J = 5.8 Hz), 2.68 (t, 2H,
J = 6.6 Hz), 1.94-1.83 (m, 2H), 1.42 (s, 18H).

13

C NMR (50 MHz, CDCl3) δ = 171.2,

155.3, 140.6, 134.0, 129.7, 128.6, 82.1, 79.9, 63.3, 55.1, 38.4, 34.4, 31.9, 28.5, 28.2.
HRMS calcd for C21H33NO5 ([M+Na]+) 402.2256, found 402.2410. [α]24D +30.7o (c 0.93,
CHCl3).
3.3.2.5. Tosylation reaction for synthesis of precusors 9a and 9b
Corresponding hydroxyl compounds 8a or 8b (1.0 equiv) in 5mL CH2Cl2 was
added Et3N (3.0 equiv) and TsCl (1.2 equiv). Reaction continued at room temperature for
20 h. The solution was diluted with CH2Cl2, washed with saturated NaHCO3 and brine.
Orangic layer was dried over MgSO4, filtered and concentrated. Purify via FC
(EtOAc/Hexanes, 2/8) to afford products as clear viscous liquid.
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COOBut
NHBoc

TsO

3.3.2.5.1.

(S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-(tosyloxy)ethyl)phenyl)

propanoate (9a)
Yield: 92%. 1H NMR (200 MHz, CDCl3) δ = 7.72 (d, 2H, J = 8.2 Hz), 7.31 (d,
2H, J = 8.0 Hz), 7.11-7.00 (m, 4H), 4.97 (d, 1H, J = 7.8 Hz), 4.48-4.36 (m, 1H), 4.19 (t,
2H, J = 7.2 Hz), 3.02 (d, 2H, J = 5.6 Hz), 2.93 (t, 2H, J = 7.2 Hz), 2.45 (s, 3H), 1.43 (s,
18H).

13

C NMR (50 MHz, CDCl3) δ = 171.0, 155.2, 144.8, 135.3, 134.9, 133.4, 130.0,

129.0, 128.0, 82.2, 79.9, 70.6, 55.0, 38.3, 35.2, 28.5, 28.1, 21.8. HRMS calcd for
C27H37NO7S ([M+Na]+) 542.2188, found 542.2221. [α]23D +28.0o (c 1.35, CHCl3).
COOBut
TsO

NHBoc

3.3.2.5.2. (S)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-(tosyloxy)propyl)phenyl)
propanoate (9b)
Yield: 75%. 1H NMR (200 MHz, CDCl3) δ = 7.79 (d, 2H, J = 8.2 Hz), 7.35 (d,
2H, J = 8.0 Hz), 7.08-6.97 (m, 4H), 4.98 (d, 1H, J = 7.6 Hz), 4.48-4.36 (m, 1H), 4.03 (t,
2H, J = 6.2 Hz), 3.00 (d, 2H, J = 5.6 Hz), 2.61 (t, 2H, J = 7.8 Hz), 2.46 (s, 3H), 2.02 -1.85
(m, 2H), 1.42 (s, 18H).

13

C NMR (50 MHz, CDCl3) δ = 171.0, 155.2, 144.9, 139.1,

134.5, 133.5, 130.0, 129.8, 128.6, 128.1, 82.2, 79.9, 69.8, 55.1, 38.4, 31.3, 30.7, 28.5,
28.2, 21.8. HRMS calcd for C28H39NO7S ([M+H]+) 534.2525, found 534.2518. [α]22D
+29.5o (c 0.40, CHCl3).
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3.3.2.6. Fluorination for synthesis of 10a and 10b
Corresponding tosylate 9a and 9b (1.0 equiv) in 5 mL acetone was added sodium
iodide (5.0 equiv). The reaction mixture was refluxed for 1 h and then filtered and
concentrated. Residue was dissolved in CH2Cl2, filtered and concentrated again to afford
clear liquid. This intermediate product was redissolved in CH3CN, silver fluoride (4.0
mmol) was added in the solution and reaction continued at room temperature for 1 d at
dark. Reaction mixture was then filtered and concentrated, purified with FC to afford
products as light yellow viscous liquids.
COOBut
NHBoc

F

3.3.2.6.1.

(S)-tert-butyl

2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethyl)phenyl)

propanoate (10a)
Yield: 50%. 1H NMR (200 MHz, CDCl3) δ = 7.18-7.05 (m, 4H), 4.99 (d, 1H, J =
7.8 Hz), 4.73 (t, 1H, 6.6 Hz), 4.53-4.35 (m, 2H), 3.10-3.00 (m, 3H), 2.93 (t, 1H, J = 6.6
Hz), 1.42 (s, 18H).

13

C NMR (50 MHz, CDCl3) δ = 171.2, 155.3, 135.9, 135.1, 130.0,

129.2, 84.2 (d, J = 168.5 Hz), 82.2, 55.1, 38.5, 36.8 (d, J = 20.0 Hz), 28.5, 28.2. HRMS
calcd for C20H30FNO4 ([M+Na]+) 390.2057, found 390.2063. [α]23D +38.0o (c 0.45,
CHCl3).
COOBut
F

NHBoc
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3.3.2.6.2.

(S)-tert-butyl

2-(tert-butoxycarbonylamino)-3-(4-(2-fluoropropyl)phenyl)

propanoate (10b)
Yield: 58%. 1H NMR (200 MHz, CDCl3) δ = 7.20-7.07 (m, 4H), 4.98 (d, 1H, J =
8.0 Hz), 4.57 (t, 1H, 6.0 Hz), 4.48-4.30 (m, 2H), 3.02 (d, 2H, J = 5.8 Hz ), 2.72 (t, 1H, J =
7.6 Hz), 2.12-1.96 (m, 2H), 1.43 (s, 18H). 13C NMR (50 MHz, CDCl3) δ = 171.2, 155.3,
139.8, 134.3, 129.9, 128.7, 83.3 (d, J = 164.0 Hz), 82.2, 79.9, 55.1, 38.4, 32.2 (d, J = 20.0
Hz), 31.1, 28.5, 28.2. HRMS calcd for C21H32FNO4 ([M+Na]+) 404.2213, found
404.2242. [α]24D +36.2o (c 1.4, CHCl3).
3.3.2.7. Deprotection reaction for synthesis of 2 and 3
Corresponding protected compound 10a and 10b (1.0 equiv) in CH2Cl2 was added
trifluoroacetic acid (TFA), stirred for 2 h to 4h at which point TLC indicated completion
of reaction. Reaction mixture was concentrated in vacuo and residue was then dissolved
in 2 mL methanol, adjust pH to 6-7 with 5% NH4OH at which point white precipitate
formed. The mixture was refrigerated overnight and then subjected to filtration, the solid
was washed with methanol and dried in vacuo to afford products as white solids.
COOH
NH2

F

3.3.2.7.1. (S)-2-amino-3-(4-(2-fluoroethyl)phenyl)propanoic acid (2)
Yield: 81%. 1H NMR (200 MHz, MeOD+TFA-D) δ = 7.17-7.05 (m, 4H), 4.58
(dt, 2H, J = 47.2, 6.2 Hz), 4.21 (dd, 1H, J = 7.6, 5.4 Hz), 3.35-3.08 (m, 2H), 2.97 (dt, 2H,
J = 24.6, 6.2 Hz). 13C NMR (50 MHz, D2O+DCl) δ = 171.0, 137.6, 132.1, 129.6, 85.1 (d,
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J = 156 Hz), 54.0, 35.6 (d, J = 19.5 Hz), 35.1. HRMS calcd for C11H14FNO2 ([M+H]+)
212.1087, found 212.1086. [α]23D -5.8o (c 0.75, 6N HCl).
COOH
F

NH2

3.3.2.7.2. (S)-2-amino-3-(4-(2-fluoropropyl)phenyl)propanoic acid (3)
Yield: 64%. 1H NMR (200 MHz, D2O+DCl) δ = 6.79-6.69 (m, 4H), 4.09 (t, 1H, J
= 6.0 Hz), 3.90-3.80 (m, 2H), 2.73(ddd, 2H, J = 14.6, 5.8, 7.6 Hz), 2.19 (t, 2H, J = 7.6
Hz), 1.59-1.31 (m, 2H). 13C NMR (50 MHz, D2O+DCl+MeOD) δ = 172.0, 142.5, 132.3,
130.5,130.2, 85.7 (d, J = 156.5 Hz), 55.0, 36.1, 32.1 (d, J = 19.0 Hz), 31.2. HRMS calcd
for C12H16FNO2 ([M+H]+) 226.1243, found 226.1256. [α]24D -5.7o (c 0.45, 6N HCl).

3.3.3.Radiosynthesis
[18F]Fluoride trapped a Sep-Pak light QMA cartridge (pre-conditioned with 10
mL 1 N NaHCO3, 10 mL water and dried with N2) was eluted with 0.6 mL
tetrabutylammonium bicarbonate (TBAHCO3) solution (21.5 mg TBAHCO3 in 0.3 mL
CH3CN and 0.3 mL H2O). The 18F activity was dried azeotropically under N2 at 110 oC.
Precursor 9a or 9b (5 mg) in 1 mL anhydrous CH3CN was then added into dried

18

F,

fluorination reaction continued for 5 min at 80 oC. After fluorination, reaction mixture
was injected to semi-preparative HPLC on Phenomenex Gemini C-18 column (10 × 250
mm, 5 µm). Intermediates [18F]10a and [18F]10b were eluted with methanol/0.1% formic
acid in water (80/20). Radioactive peak between 11 min to 13 min was collected and then
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diluted with 20-25 mL water, loaded on HLB oasis cartridge (preconditioned with 10 mL
ethanol and 10 mL water), washed with 2 mL water and then eluted with 1 mL ethanol.
Removing ethanol under N2 at 60 oC. TFA was then added, deprotection reaction
continued at 60 oC for 10 min. After removing TFA with N2 flow, 1 mL sterile water was
added to formulate final product. Chemical and radiochemical purity (RCP) were
determined by analytical HPLC performed on a Phenomenex Gemini C-18 column (4.6 ×
250 mm, 5 µm) eluted by solvent system A: methanol/0.1% formic acid (20/80) at flow
rate of 1 mL/min and TLC (NH4OH/MeOH/ CH2Cl2, 1/6/14). Retention time was 6.9 min
for [18F]2 and 7.6 min for [18F]3. Enantiomeric purity was determined with a chirobioticT (Aldrich, St. Louis, MO) chiral column (5µ, 250 × 4.6 mm) using solvent system B:
ethanol/ H2O (50/50) at flow rate of 0.5 mL/min. Retention time was 9.7 min for [18F]2
and 10.6 min for [18F]3.

3.3.4. In vitro cell uptake studies and transport characterization studies
Brain gliosarcoma cell line 9L was purchased from ATCC (Manassas, VA). The
9L cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, GIBCO BRL,
Grand Island, NY) supplemented with 10% fetal bovine serum (Hycolne, Logan, UT) and
1% penicillin/ streptomycin. Cells were maintained in T-75 culture flask under
humidified incubator conditions (37 oC, 5% CO2) and were routinely passaged at
confluence. Tumor cells were plated at a concentration of 2.0 × 105 cells/well 24 h in
culturing media prior to cell uptake and inhibition studies. On the day of experiment, the
media was aspirated and the cells were washed three times with 1 mL of warm phosphate
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buffered saline (PBS, containing 0.90 mM of Ca2+ and 1.05 mM of Mg2+). Each assay
condition was performed in triplicates.
For cell uptake studies, ligand of choice was mixed within PBS solution and was
then added to each well (~500,000 cpm/mL/well). The cells were incubated at 37 °C for
5, 30, 60, 120 min. At the end of the incubation period, the wells were aspirated free of
ligand and then the residual cells were washed 3 times with 1 mL ice cold PBS without
Ca2+ and Mg2+. After washing with ice cold PBS, 350 µL 1 M NaOH was used to lyse the
cells. The lysed cells were collected onto filter paper and counted using a gamma counter
(Packard Cobra). Together with the sample of initial dose. 100 µL of the cell lysate was
used for determination of protein concentration by Lowry method. The data was
normalized as percentage uptake of initial dose relative to 100 µg protein content (%
ID/100 µg protein).
In inhibition studies, [18F]2 was mixed with specific inhibitors in concentration of
0.5 mM, 1 mM and 5 mM in PBS solution. In sodium dependence studies, PBS buffer
was replaced with Na+ free solution (143 mM choline chloride, 2.68 mM KCl and 1.47
mM KH2PO4). The cells were incubated at 37 °C for 30 min. The procedure following
incubation was the same as in cell uptake studies. The data was normalized in reference
to uptake of [18F]2 without any inhibitor in PBS solution.

3.3.5. Biodistribution in Fisher rats with 9L glioma tumors
F344 rats were purchased from Charles Rivers Laboratory (Malvern, PA).
Xenografts using 9L cells in F344 rats were accomplished by injecting 4-5 million
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cells/xenograft. The cells suspended in PBS solution (0.2 mL) were injected
subcutaneously into each of shoulder flanks of the F344 rat. The growth of the tumor was
monitored daily for two weeks. When the volume of the tumors reached 1 cm, the rat
tumor model was used for biodistribution or microPET imaging studies. Animals were
fasted for 12-18 hours prior to the procedure. Saline solution containing the radioactive
compounds in a small volume (0.2 mL) was injected into the lateral tail vein under
isoflurane anesthesia (1-2%, 1 L/min oxygen). The animals were sacrificed at 30 and 60
min time points post-injection by cardiac excision under anesthesia. Six rats were
sacrificed at each time point. The organs of interest and tumors were removed and
weighed. The radioactivity in each tissue was measured using gamma counter together
with sample of the initial dose. Results were expressed as the percentage of the injected
dose per gram (%ID/g) of tissue. Each value represents the mean ± SD of six rats unless
otherwise noted.

3.3.6. Small animal imaging with a microPET
PET imaging studies were performed on a Phillips Mosaic small animal PET
scanner, which has an imaging field of view of 11.5 cm. Under isoflurane anesthesia (12%, 1L/min oxygen) the tumor bearing F344 rats as described before were injected with
30-37 MBq (0.8-1 mCi) of activity via an intravenous injection into the lateral tail vein.
Data acquisition began immediately following the intravenous injection. Dynamic scans
were conducted over a period of 2 h (5 min/frame; image voxel size 0.5 mm3). Rats were
visually monitored for breathing and a heating pad was used to maintain body
temperature throughout the entire procedure. Images were reconstructed and region of
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interest

(ROI)

analysis

was

performed

using

AMIDE

software

(http://amide.sourceforge.net/).

3.4. Conclusion
In summary, we prepared new optically pure phenylalanine derivatives FEP ([18F]2) and
FPP ([18F]3) in high radiochemical purity, good radiochemical yield (11-37%) and high
specific activity (21-69 GBq/µmol). Cellular uptake in 9L glioma demonstrated that FEP
had a higher uptake than FPP and previously reported FET ([18F]1). Uptake mechanism
studies suggested that accumulation of FEP into 9L cells was predominantly via system
L. In vivo biodistributon studies using rats bearing 9L glioma tumor model showed that
FEP had higher uptake in 9L glioma than surrounding organs. Small animal PET imaging
studies demonstrated that FEP was comparable to FET. These results indicate that FEP
([18F]2) is a potential useful PET tumor imaging agent.
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Chapter 4

Synthesis and comparative biological evaluation of Land D-isomers of 18F labeled fluoroalkyl phenylalanine
derivatives as tumor imaging agents
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4.1 Introduction
Amino acids are essential for growth of cancer cells as a source for energy and
building blocks for protein synthesis [1]. Unregulated amino acid transport and increased
protein synthesis rate are well-known characteristics of tumor cells. A number of amino
acids based tracers demonstrated improved imaging characteristics relative to the most
commonly used [18F]fluoro-2-deoxy-D-glucose (FDG) for certain cancers, particularly for
imaging of brain tumors because of their low uptake in cortical normal tissue and
inflammatory tissues [2, 3].
Currently, most of clinically utilized amino acid tracers for PET and SPECT are
L-isomers.

A number of L-amino acids and their derivatives have demonstrated promising

clinical results such as 11C labeled natural amino acids [11C]L-methionine (MET) [4] and
18

F or 123I labeled non-natural amino acids, 3-[123I]Iodo-α-methyl-L-tyrosine (L-[123I]IMT)

[5],

cis-4-[18F]fluoro-L-proline

[6],

L-6-[

18

F]fluoro-DOPA

[7],

anti-1-amino-3-

[18F]fluoro-cyclobutyl-1-carboxylic acid (FACBC) [8], O-[18F]fluoroethyl-L-tyrosine(LFET, [18F]1) [9, 10]. Non-natural amino acid tracers could overcome certain
shortcomings of natural amino acids resulting from short half-life of

11

C and

susceptibility to non-protein metabolic pathways. They generally exhibit increased uptake
in tumor cells while show no incorporation into protein and remain metabolically stable
in the cells [2, 11]. This suggests upregulation of amino acid transport is the dominating
process for increased uptake of non-natural amino acid tracers and incorporation into
protein is not necessary. Amino acid transport systems A (alanine preferring), ASC
(alanine-serine-cysteine preferring) and L (leucine preferring) have been found to be
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upregulated in tumor cells and they are targets of oncogene and protooncogene actions
[12, 13]. In particular, systems L amino acid transporter system (LATs), which plays a
critical role in angiogenesis, tumor growth and proliferation [14, 15], is a main focus for
developing amino acid based tumor imaging agents [2, 3, 16].
D-amino

acids have been suggested to be potentially useful tumor specific

imaging agents since 1970s. This suggestion stemmed from the observation that some 14C
labeled D-amino acids had preferred uptake in tumor-bearing mice compared to their
corresponding L-isomers [17]. Because D-amino acids are not commonly utilized in
mammalian cells, they are considered to be non-natural, their increased uptake into tumor
cells is mainly the result of over-expression of amino acid transporters [18]. It has been
shown that LAT1 (one of four subtypes of LATs), transports certain D-amino acids such
as D-phenylalanine (Phe), D-leucine (Leu) and D-methionine (Met) with high affinity [1921]. But not all subtype of LATs could tolerate D-amino acids. LAT2 for example, is
seterospecific for L-Phe, Leu, Met et al [22]. Of all subtypes of system L, LAT1 in
particular, is closely correlated with angiogenesis, cell proliferation [15] and prognosis of
patients with a variety of cancers such as astrocytoma, non-small cell lung cancer
(NSCLC) and prostate cancer [23-25]. Due to the current knowledge of transport systems,
especially about LAT1, there has been increased interest in developing D-amino acid
based tracers. The reported results in comparative studies of L- and D-amino acid
compounds are somewhat controversial. On one hand, there were studies demonstrated
low uptakes of D-amino acid tracers in tumors. D-[11C]MET was shown to have lower
uptake in brain tumors than L-[11C]MET [26]. D-FET had negligible accumulation in
mice brain [10] as well as in SW707 colon carcinoma cells [27] compared to that of the
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L-isomer.

On the other hand, there are a number of reports showing that some D-amino

acid derivatives have improved tumor-imaging properties than their corresponding Lisomers. Evaluations of O-[18F]fluoromethyl-, fluoroethyl- and fluoropropyl-tyrosine in
tumor bearing mice demonstrated D-isomers have higher tumor-to-blood or tumor-topancreas ratio [28]. Comparison of D- and L-isomer of 2-[123/125I]Iodo-tyrosine showed Disomer cleared faster from blood and had a lower overall body background [29]. 2[123I]iodo-D-phenylalanine demonstrated similar advantage over its L-isomer [30].
Moreover, several D-isomers showed preferential transport at the blood-brain barrier
(BBB) compared with their L-isomers, such as cis-4-[18F]fluoro-D-proline [31, 32] and DFET (in porcine brain)[33].
COOH
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Figure 4.1. Chemical structures of L- and D- 18F labeled tyrosine and new phenylalanine derivatives

We recently reported new
[18F]fluoroethyl)-L-phenylalanine

18

F labeled L-phenylalanine derivatives, p-(2-

(L-FEP,

L-[

18

F]2)

and

p-(3-[18F]fluoropropyl)-

phenylalanine (L-FPP, L-[18F]3) (as shown in Figure 4.1) [34]. L-FEP was shown to be
comparable in imaging rat with 9L tumors as L-FET ([18F]1), which is a clinically utilized
PET tracer for imaging brain tumor and head and neck squamous cell carcinomas [9].
The goal of this study is to evaluate the potential of D-isomer of fluoroalkyl
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phenylalanine derivatives as tumor imaging agents in comparison with their
corresponding L-isomers in vitro in 9L rat glioma cells and in vivo in rats bearing 9L
tumor models.

4.2 Results and Discussion
4.2.1 Synthesis of labeling precursors and standards
COOBut

COOBut

a

NH2

HO

NHBoc

HO

D-4

NHBoc

TfO

D-5

COOBut

c

COOBut
HO

n = 0, D-7a
n = 1, D-7b

NHBoc

n

NHBoc

n

COOBut

e
TsO

n = 1, D-8a
n = 2, D-8b

COOBut

f

D-6

d

NHBoc

n

F

COOBut

b

g

NHBoc

n

n = 1, D-9a
n = 2, D-9b

COOH
F

NH2

n

n = 1, D-2
n = 2, D-3

n = 1, D-10a
n = 2, D-10b

Scheme 4.1. Synthesis of labeling precursors and standards 2 and 3. Reagents and conditions: a)
(Boc)2 O, NaHCO3, MeOH, H2O, rt , 4h, 75%; b) Tf2 O, pyridine, CH2Cl2, 0oC, 81%; c) Tributyl
vinyltin or tributyl allyltin, LiCl, Pd(PPh3)2Cl2, DMF, 70oC, 90% (n = 0) or 94% (n = 1); d) 9BBN, THF, NaOH, H2 O2, 67% (n = 1) or 70% (n = 2); e) TsCl, Et3N, CH2Cl2, 77% (n = 1) or
84% (n = 2); f) i. NaI, acetone, reflux; ii. AgF, CH3CN, 45% (n = 1) or 79% (n = 2); g) TFA,
CH2Cl2, 52% (n = 1) or 71% (n = 2).
COOBut

COOBut
b

NHBoc

HO
D-5

F

O

NHBoc
D-12

COOH

c
F

NH2

O
D-1

a
COOBut
TsO

O

NHBoc

D-11

Scheme 4.2. Synthesis of precursor and standard 1. Reagents and conditions: a) TsO(CH2)2 OTs,
K2CO3, DMF, 70oC, 4h, 61%; b) FCH2CH2 Br, DMF, K2CO3, 70oC 2h, 76%; c) TFA, CH2Cl2,
56%.
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Here we showed the synthesis of D-isomers, preparation of corresponding Lisomers was carried out in the same manner except the starting materials were in Lisomeric form. Preparation of D-isomer of tosylate precursor and standard for labeling
FEP ([18F]2) and FPP ([18F]3) was shown in Scheme 4.1 which followed the synthesis of
its corresponding L-isomer as described in details in Chapter 3 [34]. D-2 and D-3 was 7%
and 19%. Although L-FET is well established, synthesis of cold standard for D-FET has
rarely been reported. So here we briefly described as in Scheme 4.2. It is modified from
reported procedure for L-FET by Hamacher, K. [35]. Precursor and standard for labeling
D-FET

were readily prepared via direct alkylation on phenol group of D-5 with overall

yields of 46% and 32% respectively. The optical rotation of all compounds was measured
to monitor their enantiomeric purity. The enantiomeric purity of the tosylate precursors
and standards for radiosynthesis was >95%, measured by chiral HPLC.

4.2.2 Radiolabeling of L- and D-FET, FEP and FPP
COOBut
TsO

n

X

COOH

a, b
18F

NHBoc

X
n

NH2

n = 2, X = O, D-[18F]1
n = 1, X = C, D-[18F]2
n = 2, X = C, D-[18F]3

n = 2, X = O, D-11
n = 1, X = C, D-9a
n = 2, X = C, D-9b

Scheme 4.3. Radiolabeling of D-FET ([18F]1), FEP ([18F]2) and FPP ([18F]3). Reagent and
conditions: a) TBA18F, TBAHCO3, CH3CN, 80 o C, 5 min; b) TFA, 60 oC, 10 min.

Table 4.1. Synthesis time, decay-corrected radiochemical yields (RCY), radiochemical
purity (RCP), enantiomeric purity and specific activity (EOS). *
Ligands
LLL-

and D-[18F]1

Synthesis
time (min)

RCY (%)

RCP (%)

Enantiomeric
Purity (%)

Specific activity
(GBq /µmol)

79-85

21-45

> 95

> 95

26-44

18

75-82

23-37

> 95

> 95

31-75

18

78-90

11-23

> 95

> 95

21-25

and D-[ F]2
and D-[ F]3

*Data were obtained from two to six experiments
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Radiosynthesis of

18

F-fluoroalkyl tyrosine and phenylalanine derivatives was

carried out via a two-step reaction as shown in Scheme 4.3 – non-carried-added (NCA)
nucleophilic fluorination with TBA18F and TBAHCO3 in CH3CN followed by acid
hydrolysis in TFA. This is an efficient process suitable for potential clinical applications
in the future. Intermediates were purified by semi-preparative HPLC to separate from
non-reacted

18

F fluoride, remaining precursors and by-products. After removing TFA,

final products were redissolved in water, in which pH was ~ 6. In order to achieve valid
comparative evaluation of L- and D-isomers of amino acid analogues as tumor-detecting
agents, the quality control of enantiomeric purity was a critical factor because the uptake
and kinetics of D-isomers in organs was demonstrated to be significantly different from
those of the corresponding L-isomers [28]. We determined the enantiomeric purity via
HPLC on chiral column and the configuration of both isomers was confirmed by
comparison with those standard “cold” compounds. In additional, radiochemical purity
was analyzed via HPLC on C-18 column and TLC. The results of radiosythesis
(summarized in Table 4.1) demonstrated optically and chemically pure tracers (purity
was > 95%) were efficiently prepared with moderate to good radiochemical yield (1145%) and high specific activity (21-75 GBq/µmol).
It is noteworthy to point out that our initial attempts to carry out nucleophilic
fluorination reaction using Kryptofix K[2.2.2]18F and K2CO3 in acetonitrile at 90 oC led
to significant racemization. There were 28-35% of the final products in the epimerized
form. To investigate the source of racemization, we examined the ratio of L- and Disomer after fluorination reaction as well as in final products measured by chiral HPLC
(Figure 4.2). The HPLC profiles showed that racemization occurred in the first step –
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fluorination reaction, the intermediates were mixtures of L- and D- isomers. Moreover,
the ratio of L- and D-isomer was the same for the fluorinated intermediates and the final
products, which suggest no further racemization occurred during acid deprotection. In
nucleophilic fluorination, the pH of K[2.2.2]18F/K2CO3 solution is ~ 10, thus the
racemization reaction is likely a base-catalyzed reaction. It was reported that factors such
as pH and temperature of the reaction solution affect the rate of racemization [36]. Higher
pH and temperature lead to faster racemization. In order to obtain the optically pure
ligands, we then carried out fluorination reaction using TBA18F/TBAHCO3 in CH3CN at
80 oC, pH of this reaction solution is ~ 8, much lower than that of K[2.2.2]18F/K2CO3
solution. Under this condition, the enantiomerically purity of ligands was improved to
>95%, which could be considered to be optically pure, as shown in Figure 4.3.

Figure 4.2. HPLC profile of fluorination intermediate [18F]10a (a) and final products FEP ([18F]2) (b)
under condition using K[2.2.2]/K18F at 90 oC for radiofluorination. Blue or red colored line is the result
from radioactive detector and black line is the result from UV trace of coinjection with standard
compounds.
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Figure 4.3. HPLC profile with L-isomer (a) and D-isomer (b) of FEP ([18F]2). Blue or red colored line is
the result from radioactive detector and black line is the result from UV trace of coinjection with “cold”
standards.

4.2.3 Cell uptake studies
We evaluated L- and D- isomers of new phenylalanine derivatives FEP ([18F]2)
and FPP ([18F]3) by examining their time dependent uptake of in 9L glioma cells. Their
uptake was compared with L- and D-FET ([18F]1), for which comparative uptake studies
have been reported before [27, 33]. Uptake of tracers was measured at selective time
points up to 2 h and the results were summarized in Figure 4.4. L-isomers showed a fast
initial uptake, quickly reached maximum uptake within 60 min and then washed out. In
contrast, D-isomers had slow linear uptake over 2 h period. Uptake of L-isomer was
significantly higher (4.3 to 16.0 fold) than that of the corresponding D-isomers, which is
consistent with other reported in vitro studies comparison L and D-isomers of tyrosine
derivatives [27, 37]. These results suggested that the cellular uptake of amino acid tracers
was mediated via highly stereo-specific amino acid transport systems.
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Figure 4.4. Comparative cellular uptake of L- and D-FET ([18F]1) (a), L- and D-FEP ([18F]2) (b) and L- and
18
D-FPP ([ F]3) (c) in 9L glioma cells. The uptake value was represented as %uptake/100 ug protein, mean
± SD.

Uptake of L and D-FPP ([18F]3) was comparable to that of corresponding isomer
of FET ([18F]1), while uptake of [18F]FEP ([18F]2) was notably higher. Maximum uptake
of L-FEP was 1.4 fold of L-FET and D-FEP was 5.2 fold of D-FET. The difference
between L- and D- isomers is the smallest in FEP. The major differences among these
tracers are lipophilicity and fluoroalkyl chain length. Tracers’ lipophilicity follows the
order of FPP (Log D = -0.73) > FEP (Log D = -1.00)>FET (Log D = -1.51) [10] while
alkyl chain length follows the order of FEP <FET ≈ FPP. From the uptake result, it
appears that a shorter fluoroalkyl chain length might be more desirable for aromatic
amino acid tracers. These results suggested both isomers of FEP ([18F]2) may worth
further investigations.

4.2.4 Transport characterization studies
Amino acid transport systems play an essential role in uptake of amino acid
ligands in tumor cells. An amino acid tracer could be substrate for a number of amino
acid transport systems with overlapping substrate selectivity. To examine and compare
- 104 -

the amino acid transport systems involved in uptake of L- and D-FEP ([18F]2), we
conducted a series of inhibition studies and sodium dependence studies in 9L glioma. The
uptake of FEP was measure in absence as well as in the presence of 0.5 to 5 mM of
specific inhibitor (as shown in Figure 4.5.). We focus on system A, ASC and L because
the transport of neutral amino acids in mammalian cells is predominantly through these
systems and they are most commonly upregulated amino acid transport systems in cancer
cells [12, 14].

Figure 4.5. Transport characterization studies of L- and D-FEP ([18F]2) in 9L glioma cells. Results were
normalized to uptake of each isomer’s uptake in PBS solution at 30 min. Data was expressed as mean ± SD
(n = 3).

The uptake of L- and D-FEP ([18F]2) was not affected by presence of N-methyl-αaminoisobutyric acid (MeAIB), which is a specific inhibitor for system A. The uptake of
both isomers exhibited similar concentration dependent inhibition by system ASC
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inhibitors L-serine (Ser) and L-alanine (Ala). However, L-FEP was more affected by the
presence of inhibitors in comparison with D-FEP, for example, 5 mM of L-Ser could
inhibit 90% of uptake of L-FEP while it can only reduce 67% uptake of D-isomer. Both
isomers uptake was strongly inhibited by 2-amino-bicylo[2.2.1]heptane-2-carboxylic acid
(BCH), a selective inhibitor of LATs. 5 mM of BCH could inhibit 98% and 94% uptake
of L- and D-FEP respectively. Since BCH is not only an inhibitor for sodium independent
system L but also an inhibitor for sodium dependent system B0 and B0,+ [38], we then
conducted sodium dependence studies to examine the contribution from sodium
dependent transport systems. Uptake of both isomers remained unchanged when
replacing PBS solution with Na+-free buffer (NaCl was replaced with choline chloride as
reported [22]. These results suggest that L- and D-FEP are selective substrates for LATs.
There are four subtypes of system L amino acid transport systems isolated and
characterized, with differences in topology, substrate selectivity and tissue distribution,
designated LAT1 to LAT4 [39]. LAT1 has attracted special interests because its
expression is rarely detected in non-tumor areas and is closely correlated with
angiogenesis, cell proliferating and prognosis of certain cancers [24, 25]. We were
especially interested in LAT1 since it is known that LAT1 could transport D-isomers of
phenylalanine, in contrast, the other subtype LAT2 could not. D-Met [40], a specific
inhibitor for LAT1, had very similar impact on uptake of L-FEP as BCH. It was not as
potent as BCH towards D-isomer, 5 mM of D-Met could inhibit 86% of the uptake.
Inhibition using N-ethylmaleimide (NEM), an inhibitor for LAT2 to LAT4 but not LAT1
[39], had dramatically different effect on uptake of L- and D-FEP. While uptake of Disomer was strongly inhibited by NEM with maximum inhibition of 92% at 5 mM
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concentration, uptake of L-isomer could only reduced up to 30%. These results indicated
that L-FEP preferred system L subtype LAT1 but D-FEP did not exhibit the same
preference. D-FEP appears to have different transport characteristics from D-Phe since it
has been reported that LAT2, LAT3 and LAT4 could not transport D-Phe [39, 41]. Of
four subtypes, LAT3 is the most sensitive to NEM inhibition (80% inhibition in
comparison to 40% for LAT2 and LAT4 or 20% for LAT1 at 5 mM concentration) [39].
This might indicate LAT3 is involved in the transport of D-FEP in addition to LAT1.

4.2.5. Small animal PET imaging studies

Figure 4.6a. Small animal PET images of L-FEP (A) and D-FEP (B) in tumor bearing rats. Color-coded
PET images from summed 2 hour data in transverse, coronal and sagittal view from left to right followed
injection of L- and D-FEP ([18F]2) are shown. The arrowhead points to the 9L xerographs.
a
Experiment carried out by Brian Lieberman [42]
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From in vitro studies results, L- and D-FEP ([18F]2) seemed to have potential as
promising tumor-imaging agents, so we continued to carried out in vivo small animal
PET imaging studies to compare these isomers’ imaging properties. Fisher rats bearing
9L tumor model was used because it is a well-established animal model mimicking
clinical glioblastoma multiform. Imaging studies could provide in vivo distribution data
consistent with tissue dissection method. From this PET imaging study, we could assess
and compare the accumulation of L- and D-FEP in 9L tumor and their in vivo kinetics.

Figure 4.7. Time activity curves of L-FEP (a) and D-FEP (b) in the rat bearing 9L tumors.
a
Experiment carried out by Brian Lieberman [42].

Data were acquired from rats administered ~37MBq (1 mCi) of L- or D-FEP
([18F]2) via tail vein injection (Figure 4.6). Time-activity curves were generated by region
of interest analysis to assess the kinetics (Figure 4.7). Results demonstrated 9L tumor
could be imaged using either L- or D-FEP. Kinetics of L- and D-isomers were similar in
that both tracers quickly reached the stable distributions within 20 min in tumor, heart
and muscle. L-isomer showed slow increase in tumor uptake after 20 min while D-isomer
exhibited slow increase in muscle uptake. L-FEP had higher uptake in tumor but the
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difference was not very significant. However, D-FEP had higher uptake in muscle than
the L-isomer, which results tumor-to-muscle ratio of D-FEP is lower in comparison to its
L-isomer

(Figure 4.8). This result is different from a number of other reports on tyrosine

and phenylalanine derivatives that D-isomers had lower uptake in normal tissue, which
leads to better contrast in imaging [28, 37, 43, 44].

Figure 4.8. Comparison of tumor to muscle ratio of L- and D-FEP and in the rat bearing 9L tumors.

4.3. Conclusions
In conclusion, we prepared new enantiomerically and radiochemically pure Land D-isomers of fluoroalkyl tyrosine and phenylalanine derivatives with good
radiochemical yield and high specific activity. Cell uptake studies in 9L glioma
demonstrated L-isomers had much faster and higher uptake in comparison with the
gradual linear uptake of D-isomers over 2 h period. FEP ([18F]2) had significantly higher
uptake than FET ([18F]1) in corresponding isomeric forms. Transport characterization
studies suggested that accumulation of L- and D-FEP into 9L cells was predominantly via
system L; L-FEP showed preferential uptake via LATs’ subtype LAT1 but its D-isomer
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did not exhibit the same preference. Small animal PET imaging studies using rats bearing
9L glioma tumor model demonstrated that both L- and D-FEP had higher uptake in 9L
tumor than surrounding tissues, but D-FEP did not exhibit improved imaging
characteristics than its corresponding L-isomer.

4.4. Materials and Methods
Details regarding General, Radiosynthesis procedure, In vitro cell uptake and
transport characterization studies in 9L cells and Small animal PET imaging was the
same as what described in Chapter 3, Section 3.3.

4.4.1. Synthesis of precursors and standards for labeling
The synthesis of L-isomers of 2 and 3 was described in Chapter 3, section 3.2.2.
The corresponding D-isomers followed the same procedure and here we would present
the NMR data on D-isomers.

COOBut
HO

NHBoc

4.4.1.1 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)propanoate (5)
1

H NMR (200 MHz, CDCl3) δ = 7.04 (d, 2H, J = 8.6 Hz), 6.75 (d, 2H, J = 8.6 Hz), 4.98

(d, 1H, J = 8.0 Hz), 4.43-4.36 (m, 1H), 2.98 (d, 2H, J = 5.8 Hz), 1.43 (s, 18H). [α]23D 39.7o (c 0.39, CHCl3).
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COOBut
TfO

4.4.1.2

NHBoc

(R)-tert-butyl2-(tert-butoxycarbonylamino)-3-(4-(trifluoromethylsulfonyloxy)

phenyl)propanoate (6)
1

H NMR (200 MHz, CDCl3) δ = 7.28 (d, 2H, J = 8.8 Hz), 7.19 (d, 2H, J = 9.0 Hz), 5.07

(d, 1H, J = 7.2 Hz), 4.53-4.37 (m, 1H), 3.07 (d, 2H, J = 6.0 Hz), 1.42 (s, 9H), 1.38 (s, 9H).
[α]24D -29.0o (c 1.0, CHCl3).

COOBut
NHBoc

4.4.1.3.1 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-vinylphenyl)propanoate (7a)
1

H NMR (200 MHz, CDCl3) δ = 7.34 (d, 2H, J = 8.0 Hz), 7.14 (d, 2H, J = 8.2 Hz), 6.70

(dd, 1H, J = 17.6, 10.8 Hz), 5.73 (d, 1H, J = 17.6 Hz), 5.23 (d, 1H, J =10.8 Hz), 4.99 (d,
1H, J = 7.8 Hz), 4.54-4.37 (m, 1H), 3.05 (d, 2H, J = 6.0 Hz), 1.43 (s, 18H). [α]24D -40.0o
(c 1.0, CHCl3).
COOBut
NHBoc

4.4.1.3.2 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-allylphenyl)propanoate (7b)
1

H NMR (200 MHz, CDCl3) δ =7.26-7.10 (m, 4H), 6.06-5.85 (m, 1H), 5.10 (d, 1H, J =

5.8 Hz), 5.08-4.96 (m, 2H), 4.54-4.37 (m, 1H), 3.36 (d, 2H, J = 6.8 Hz) 3.03 (d, 2H, J =
6.0 Hz), 1.43 (s, 18H). [α]24D -34.8o (c 0.50, CHCl3).
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COOBut
NHBoc

HO

4.4.1.4.1

(R)-tert-butyl

2-(tert-butoxycarbonylamino)-3-(4-(2-hydroxyethyl)phenyl)

propanoate (8a)
1

H NMR (200 MHz, CDCl3) δ =7.20-7.08 (m, 4H), 4.99 (d, 1H, J = 6.8 Hz), 4.52-4.37

(m, 1H), 3.85 (t, 2H, J = 6.6 Hz), 2.98 (d, 2H, J = 5.8 Hz), 2.85 (t, 2H, J = 6.6 Hz), 1.42
(s, 18H). [α]21D -41.7o (c 0.75, CHCl3).

COOBut
HO

NHBoc

4.4.1.4.2 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-hydroxypropyl)phenyl)
propanoate (8b)
1

H NMR (200 MHz, CDCl3) δ =7.15-7.06 (m, 4H), 5.00 (d, 1H, J = 7.8 Hz), 4.49-4.37

(m, 1H), 3.67 (t, 2H, J = 6.4 Hz), 3.02 (d, 2H, J = 6.0 Hz), 2.68 (t, 2H, J = 6.6 Hz), 1.941.83 (m, 2H), 1.42 (s, 18H). [α]24D -30.4o (c 0.95, CHCl3).

COOBut
NHBoc

TsO

4.4.1.5.1 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-(tosyloxy)ethyl)phenyl)
propanoate (9a)
1

H NMR (200 MHz, CDCl3) δ =7.72 (d, 2H, J = 8.2 Hz), 7.31 (d, 2H, J = 8.0 Hz), 7.11-

7.00 (m, 4H), 4.97 (d, 1H, J = 7.8 Hz), 4.48-4.36 (m, 1H), 4.19 (t, 2H, J = 7.2 Hz), 3.02
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(d, 2H, J = 5.6 Hz), 2.93 (t, 2H, J = 7.2 Hz), 2.45 (s, 3H), 1.43 (s, 18H). [α]23D -29.0o (c
0.87, CHCl3).

COOBut
TsO

NHBoc

4.4.1.5.2 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-(tosyloxy)propyl)phenyl)
propanoate (9b)
1

H NMR (200 MHz, CDCl3) δ =7.79 (d, 2H, J = 8.2 Hz), 7.35 (d, 2H, J = 8.0 Hz), 7.08-

6.97 (m, 4H), 4.97 (d, 1H, J = 7.6 Hz), 4.48-4.36 (m, 1H), 4.03 (t, 2H, J = 6.2 Hz), 3.00
(d, 2H, J = 5.8 Hz), 2.62 (t, 2H, J = 7.6 Hz), 2.46 (s, 3H), 2.04 -1.86 (m, 2H), 1.43 (s,
18H). [α]23D -27.7o (c 0.35, CHCl3).

COOBut
NHBoc

F

4.4.1.6.1

(R)-tert-butyl

2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethyl)phenyl)

propanoate (10a)
1

H NMR (200 MHz, CDCl3) δ = 7.18-7.05 (m, 4H), 4.99 (d, 1H, J = 7.8 Hz), 4.73 (t, 1H,

6.6 Hz), 4.53-4.35 (m, 2H), 3.10-3.00 (m, 3H), 2.93 (t, 1H, J = 6.6 Hz), 1.42 (s, 18H).
[α]23D -38.7o (c 0.47, CHCl3).

COOBut
F

NHBoc
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4.4.1.6.2 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-fluoropropyl)phenyl)
propanoate (10b)
1

H NMR (200 MHz, CDCl3) δ =7.20-7.07 (m, 4H), 4.99 (d, 1H, J = 7.2 Hz), 4.57 (t, 1H,

6.0 Hz), 4.48-4.30 (m, 2H), 3.02 (d, 2H, J = 5.8 Hz ), 2.72 (t, 1H, J = 7.6 Hz), 2.12-1.96
(m, 2H), 1.42 (s, 18H). [α]24D -37.0o (c 0.90, CHCl3).

COOH
NH2

F

4.4.1.7 (R)-2-amino-3-(4-(2-fluoroethyl)phenyl)propanoic acid (2)
1

H NMR (200 MHz, D2O+DCl) δ = 6.89-6.77 (m, 4H), 4.23 (dt, 2H, J = 47.0, 6.2 Hz),

3.90 (t, 1H, J = 6.6 Hz), 2.81 (ddd, 2H, J = 14.6, 5.4, 7.6 Hz), 2.54 (dt, 2H, J = 27.4, 6.0
Hz). [α]23D +5.8o (c 0.5, 6N HCl).

COOH
F

NH2

4.4.1.8 (R)-2-amino-3-(4-(2-fluoropropyl)phenyl)propanoic acid (3)
1

H NMR (200 MHz, D2O+DCl) δ = 7.04-6.94 (m, 4H), 4.34 (t, 1H, J = 6.0 Hz), 4.13-

4.04 (m, 2H), 2.98 (ddd, 2H, J = 14.6, 5.8, 7.6 Hz), 2.44 (t, 2H, J = 7.6 Hz), 1.84-1.57 (m,
2H). [α]24D +6.0o (c 0.45, 6N HCl).

COOBut
TsO

NHBoc

O
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4.4.1.9 (R)-tert-butyl 2-(tert-butoxycarbonylamino)-3-(4-(2-(tosyloxy)ethoxy)phenyl)
propanoate (11)
D-Boc-tyrosine-tert-butyl

ester (5, 1.0 equiv) was dissolved in 5mL dry DMF.

K2CO3 (3.0 equiv) and 1,2-bis(tosyloxy)ethane (2.0 equiv) was added sequentially. The
mixture was stirred at 70 oC for 4h. After reaction, reaction solution was diluted with 60
mL ether, washed with 10 mL water and 10 mL brine. Organic layer dried over MgSO4
and solvent was removed under reduced pressure. Crude mixture was purified by FC
(MeOH/CH2Cl2, 1:200) to give final product D-11 as white foam. D-11, 1H-NMR (200
MHz, CDCl3): δ = 7.83 (d, 2H, J = 8.4 Hz), 7.35 (d, 2H, J = 8.0 Hz), 7.06 (d, 2H, J = 8.6
Hz), 6.70 (d, 2H, J = 8.6 Hz), 4.98 (d, 1H, J = 8.2 Hz), 4.42-4.34 (m, 3H), 4.13 (t, 2H, J =
4.8 Hz), 2.98 (d, 2H, J = 5.8 Hz), 2.46 (s, 3H), 1.43 (s, 18H). [α]21D -24.2o (c 1.05,
CHCl3).

In

comparison,

(S)-tert-butyl

2-(tert-butoxycarbonylamino)-3-(4-(2-

(tosyloxy)ethoxy)phenyl)propanoate (L-11), 1H-NMR (200 MHz, CDCl3): δ = 7.83 (d,
2H, J = 8.4 Hz), 7.35 (d, 2H, J = 8.0 Hz), 7.06 (d, 2H, J = 8.6 Hz), 6.70 (d, 2H, J = 8.6
Hz), 4.98 (d, 1H, J = 8.2 Hz), 4.42-4.34 (m, 3H), 4.13 (t, 2H, J = 4.8 Hz), 2.98 (d, 2H, J =
5.8 Hz), 2.46 (s, 3H), 1.43 (s, 18H). 13C NMR (50 MHz, CDCl3) δ = 171.1, 157.2, 155.3,
145.1, 133.2, 130.7, 130.0, 129.5, 128.2, 114.7, 82.2, 79.8, 68.3, 65.7, 55.2, 37.8, 28.5,
28.2, 21.8. HRMS calcd for C27H37NO8S ([M+Na]+) 558.2138, found 558.2130. [α]21D
+21.6o (c 0.75, CHCl3).

COOBut
F

4.4.1.10

(R)-tert-butyl

NHBoc

O

2-(tert-butoxycarbonylamino)-3-(4-(2-fluoroethoxy)phenyl)

propanoate (12)
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D-Boc-tyrosine-tert-butyl

ester (5, 1.0 equiv) was dissolved in 8 mL DMF. K2CO3

(325 mg, 3.0 equiv) and 1-bromo-2-fluoroethane (2.0 equiv) were added sequentially.
The mixture was stirred at 70 oC for 4 h. After reaction, reaction mixture was diluted with
60 mL ether and washed with 10 mL water and 10 mL brine. Organic layer dried over
MgSO4 and solvent was removed under reduced pressure. Resulting product D-12 was a
clear viscous liquid. D-12, 1H-NMR (200 MHz, CDCl3): δ = 7.10 (d, 2H, J = 8.6 Hz),
6.86 (d, 2H, J = 8.6 Hz), 4.97 (d, 1H, J = 8.0 Hz), 4.75 (dt, 2H, J1 = 47.2 Hz, J2 =4.2 Hz),
4.42-4.28 (m, 1H), 4.20 (dt, 2H, J1 = 27.6 Hz, J2 =4.2 Hz), 2.98 (d, 2H, J = 5.8 Hz), 1.43
(s, 18H). [α]23D -35.0o (c 0.42, CHCl3). In comparison, (S)-tert-butyl 2-(tertbutoxycarbonylamino)-3-(4-(2-fluoroethoxy)phenyl)propanoate (L-12),

1

H-NMR (200

MHz, CDCl3): δ = 7.10 (d, 2H, J = 8.6 Hz), 6.86 (d, 2H, J = 8.6 Hz), 4.97 (d, 1H, J = 8.0
Hz), 4.75 (dt, 2H, J1 = 47.2 Hz, J2 =4.2 Hz), 4.42-4.28 (m, 1H), 4.20 (dt, 2H, J1 = 27.6
Hz, J2 =4.2 Hz), 2.98 (d, 2H, J = 5.8 Hz), 1.43 (s, 18H). 13C NMR (50 MHz, CDCl3) δ =
171.2, 157.7, 155.3, 130.8, 129.4, 114.8, 82.2, 82.1 (d, J = 169.5 Hz), 79.9, 67.4 (d, J =
20.5 Hz), 55.2, 37.9, 28.5, 28.2. HRMS calcd for C20H30FNO5 ([M+Na]+) 406.2006,
found 406.2042. [α]23D +32.1o (c 0.40, CHCl3).

COOH
F

NH2

O

4.4.1.11 (R)-2-amino-3-(4-(2-fluoroethoxy)phenyl)propanoic acid (1)
D-12

(1.0 equiv) was dissolved in CH2Cl2 and equal volume of trifluoroacetic

acid was added and reaction mixture was stirred in room temperature for 4 h. Upon
completion, reaction mixture was concentrated under reduced pressure. Resulting solid
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was dissolved in methanol and pH of the solution was adjusted to ~7 with 5% NH4OH to
form a white precipitate was formed. The suspension was kept overnight at 0 oC and
filtered to afford D-1 as whit solid. D-1, 1H-NMR (D2O+DCl): δ = 6.92 (d, 2H, J = 8.8
Hz), 6.66 (d, 2H, J = 8.8 Hz), 4.44 (dt, 2H, J1 = 47.4 Hz, J2 = 4.0 Hz), 4.05-3.98 (m, 2H),
3.87 (t, 1H, J = 4.0 Hz), 2.89 (ddd, 2H, J = 14.6, 5.6, 7.4 Hz). [α]23D +3.2o (c 0.5, 6 N
HCl). In comparison, (S)-2-amino-3-(4-(2-fluoroethoxy)phenyl)propanoic acid (L-1), 1HNMR (Acetic acid-d4): δ = 7.24 (d, 2H, J = 8.6 Hz), 6.91 (d, 2H, J = 8.6 Hz), 4.73 (dt,
2H, J1 = 47.4 Hz, J2 =4.0 Hz), 4.40 (dd, 1H, J1 = 7.6 Hz, J2 = 5.2 Hz), 4.22 (dt, 2H, J1 =
29.2 Hz, J2 = 4.0 Hz), 3.52-3.22 (m, 2H). 13C NMR (50MHz, Acetic acid-d4): δ = 173.1,
158.2, 130.8, 126.9, 115.0, 81.9 (d, J = 167.5 Hz), 67.2 (d, J = 20.0 Hz), 55.8, 35.1.
HRMS calcd for C11H14FNO3 ([M+H]+) 228.1036, found 228.1265. [α]23D -3.4o (c 0.53,
6 N HCl).

4.4.2. Log D measurement
Partition coefficient was measured by mixing ligand with 3 g each of 1-octanol
and sodium phosphate buffer (0.1 M, pH 7.4) in a test tube. The test tube was vortexed
for 3 min at room temperature, followed by centrifuge for 5 min. Two weighted samples
from 1-octanol and buffer layers were counted in a gamma counter. The partition
coefficient was determined by calculating the ratio of cpm/g of 1-octanol to that of buffer.
The measurement was done in duplicates.
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Chapter 5

Radiosynthesis and in vitro evaluation of 11C labeled
ethanolamine derivatives as potential tumor imaging
agents for PET

- 122 -

5.1 Introduction
Cancer cells exhibit significantly altered phospholipids metabolism compared
with normal counterparts [1, 2]. Proliferating tumor cells have increased demand for
phosphoglycerides that are essential in formation of cellular membranes. The most
abundant phosphoglycerides in higher plants and animals are phosphatidylethanolamine
(PtdEt) and phosphatidylcholine (PtdCho), which contain ethanolamine and choline as
polar head group respectively [3].
Numerous

31

P-Magnetic resonance spectroscopic (MRS) studies have detected

high levels of phoshphomonoester (PME) including phosphocholine (PCho) and
phosphoethanolamine (PEt) in cancer cells [1, 2]. PCho, the product of choline kinase, is
the first intermediate in the incorporation of choline into PtdCho through Kennedy
pathway [4]. The increased concentration of PCho in cancer cells is largely due to
upregulation and increased enzyme activity of choline kinase [5-7] and choline
transporters [8]. Based on this aberrant tumor phospholipid metabolism, radiolabeled
[11C]choline (CH) [9] and its

18

F labeled derivatives fluoromethyl choline (FCho) and

fluoroethyl choline (FEC) [10] (Figure 5.1) have been developed and successfully used
for detection and staging various tumors including brain tumors and prostate cancers,
which could improve on tumor detectability of most widely used FDG-PET [11, 12].
Cl

H311C
N

[11C]Choline (CH)

Cl
OH

18F

N

OH

[18F]fluoromethyl choline (FCH)

Figure 5.1. Radiolabeled choline and its derivatives
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18F

Cl
N

OH

[18F]fluoroethyl choline (FEC)

Recent development of proton-decoupled 31P-MRS method enabled the resolution
of PEt and PCho peaks in vivo that were previously overlapped under the broad PME
peak [13, 14]. This advance led to the discovery that PEt level in a number of cancers is
significantly higher than PCho. For example, in human non-Hodgkin’s lymphoma (NHL)
the PEt/PCho ratio of 2.9 has been reported (Figure 5.2) [15]. Prevailing contribution
from PEt in elevated PME signal has also been observed in various breast cancers [16,
17] and pediatric brain tumors [18]. This observation of higher concentration of PEt in
tumor cells might indicate that ethanolamine, the precursor for PEt, could potentially
more sensitive than choline as a probe for phospholipids metabolism.

In order to validate the potential of radiolabeled ethanolamine for cancer
detection, we initially carried out in vitro studies using
compared uptake of [14C]ethanolamine (EA),

14

C label compound. We

[14C] N, N’-dimethyl ethanolamine

(DMEA) and [14C]choline (CH) in a wide variety of cancer cell lines including colorectal
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cancer (HCT116), prostate (PC-3), melanoma (A375 and 1618), glioblastoma (SF767,
A172), and lymphoma (DLCL2). Our results showed that [14C]EA and [14C]DMEA had
significantly higher uptake than choline and their uptake depends on the proliferating
status of the cells [19]. These preliminary results encouraged us to develop the
corresponding 11C labeled PET imaging agents (Figure 5.3). As consideration for ease of
radiosynthesis, in this work we prepared [11C]N-methylethanolamine (MEA) and
[11C]DMEA and carried out biological studies in vitro. In vivo biodistribution studies and
imaging studies are in progress.

5.2 Results and Discussion
5.2.1 Comparison of 14C labeled choline and ethanolamine as probe for
cancer detection
Table 5.1. Cell type and their origins
Cell lines

Cell Type

Cell Origin

SF767

Glioblastoma Multiforme

Human Brain

A172

Glioblastoma Multiforme

Human Brain

1618

Melanoma

Human Skin

A375

Melanoma

Human Skin

PC3

Androgen Independent Prostate Carcinoma

Human Prostate

LnCap

Androgen Dependent Prostate Carcinoma

Human Prostate

DLCL2

Diffuse Large B-cell Lymphoma

HCT116

Colorectal Adenocarcinoma

Human Lymph Node
Human Colon

In vitro uptake studies were carried out with [14C]EA, [14C]DMEA and [14C]CH
in a diversity of human tumor cell lines, including two glioblastoma lines, an androgen
dependent and an androgen independent prostate adenocarcinoma, two melanoma cell
lines, a colorectal cancer cell line and a diffuse large B-cell lymphoma cell line (as shown
in Table 5.1). Uptake of [14C]MEA was compared to that of [14C]CH in two prostate
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cancer cell lines as well. Results showed that in all tumor cell lines tested, [14C]EA and
its derivatives had significant higher uptake (1.4 to 7.4) than [14C]CH (Figure 5.4).

Figure 5.4a. Normalized uptake of [14C]EA, [14C]DMEA and [14C]MEA relative to [14C]CH in tumor cell
lines.
a
Uptake studies of [14C]EA, [14C]DMEA and [14C]CH were carried out by Akiva Mintz [19].
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Figure 5.5a. Cellular uptake studies of [14C]CH and [14C]EA in A172 cells. Time course studies (A) and
after 60 min, replacing tracer-containing media with regular media (B).
a
Experiment carried out by Akiva Mintz [19].
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We performed time course studies of [14C]EA and [14C]CH in A172 cells, which
demonstrated continuous linear uptake of [14C]EA after 4 hours of tracer exposure
(Figure 5.5A). However, if the radiotracer was removed after 60 minutes, and replaced
with non-tracer containing media, the radioactive counts in the cells were not
significantly different after 180 minutes compared to immediately after 60 minutes of
tracer incubation (Figure 5.5B). These results suggested the irreversible trapping of
ethanolamine in tumor cells.
The preliminary results using

14

C labeled ligands demonstrate for the first time

that ethanolamine and its derivatives could be potential useful oncologic imaging tracers
for a number of cancers including brain and prostate cancer. Based on these findings, we
then continued with preparation of 11C labeled ethanolamine tracers that could potentially
be utilized as PET imaging agents.

5.2.2 Radiolabeling of [11C]EA, [11C]MEA and [11C]DMEA
11CO

H2
2

Ni, 400 oC

O

11CH

NH3
4

Pd, 1000

Na11CN, EtOH
O

Cl

80 oC, 5 min

NaOH

H11CN

Na11CN

oC

O

LiAlH4, THF
O

11CN

NH211CH2CH2OH

rt, 6 min
[11C]EA

Scheme 5.1a. Radiolabeling of [11C]EA.
a
Synthesis carried out by Datta Ponde

Radiosynthesis of [11C] EA, [11C]MEA and [11C]DMEA was carried out as shown
in Scheme 5.1 and Scheme 5.2. [11C]EA was recently synthesized by Dr. Datta Ponde
employing procedure reported by Thorell et al with modifications [20].
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11CH

3I,

I2
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720 °C

CH3CN
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OH

11CH

3I,

CH3CN

45 oC, 5 min

11CH

3I

H311C

N
H

OH

[11C]MEA
H311C

N

OH

[11C]DMEA

Scheme 5.2. Radiolabeling of [11C]MEA and [11C]DMEA

[11C]MEA and [11C]DMEA were labeled through methylation of ethanolamine
and N-methylethanolamine respectively with [11C]CH3I prepared from [11C]CO2 using
GE MeI box. Although these molecules have simple structure, the short half-life of

11

C

posts strict limit on reaction time – within 20 min (one half-life period) is preferable. In
additional, [11C]CO2 produced in a cyclotron target is not suitable labeling precursor for
the synthesis of these ligands and need to be converted into [11C]NaCN or [11C]CH3I for
radiosynthesis. We were able to prepare radiochemically pure (>95%) [11C]MEA and
[11C]DMEA within 20 min from end of bombardment (EOB) with good specific activity
(~52 GBq/µmol or 1300 Ci/mmol) and high radiochemical yield (average 45 to 52%,
decay corrected). Radiolabeled ligands were purified with silica cartridge. Radiochemical
purity was analyzed by HPLC and TLC. The labeling procedure was carried out in
automated synthetic module and is suitable for potential clinical applications. Several
problems associated with purification and detection of these compounds made this
seemly straightforward radiosynthesis an interesting challenge. We conducted a series of
experiment to optimize their reaction condition, purification process and quality control.
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5.2.2.1 Reaction condition studies
Table 5.2: Effect of temperature on radiolabeling of [11C]MEA and [11C]DMEA
Product

Temp (°C)

Radiochemical purity (%)

11

25

No reaction

1

11

60

>95

>3

11

25

No reaction

1

11

45

>95

2

11

50

>95

>3

11

55

93±3

2

11

[ C] DMEA

60

60±5

2

[11C] DMEA

65

19±3

2

[ C] MEA
[ C] MEA
[ C] DMEA
[ C] DMEA
[ C] DMEA
[ C] DMEA

Experiments

Temperature was a key factor in this labeling reaction (Table 5.2). No reaction
was observed at room temperature in presence of base (NaOH or KOH) or without base.
After careful increase of temperature it was observed that for the synthesis of [11C] MEA,
reaction can be carried out at 60°C. However, in the case of [11C]DMEA, reaction should
best be set between 45 to 55°C. At higher temperature (> 60°C), we have detected the
formation of [11C]CH (HPLC result Figure 5.6 as example) (50% to 80% in the final
product as seen from analytical HPLC).

Figure 5.6. Formation of [11C]CH in radiosynthesis of [11C]DMEA at high temperature.
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No base is required for this methylation reaction. A number of bases such as
sodium hydroxide, potassium hydroxide and sodium hydride were tried initially, but no
advantage was found, moreover, sodium hydride can produce the O-methylation side
products. We also tried different solvents such as DMF, DMSO and CH3CN, reaction
time and yields were similar in these solvents. Since it is often more difficult to remove
DMF and DMSO, we choose CH3CN as reaction solvent.

5.2.2.2 Purification of [11C]MEA and [11C]DMEA
Table 5.3. Experimented purification methods and results
Purification methods

Results and comments

Sep-Pak C18 (light or plus) cartridges

could not appropriately trap products

Weak cation exchange cartridges

could not appropriately trap products

Strong cation exchange cartridge

could not be eluted with appropriate solvent

Semi-prep HPLC with cyano column
Silica cartridges

could not elute the products using water
retained products and then eluted with saline

For the purification of [11C]MEA and [11C]DMEA, we tried a number of
cartridges such as Sep-Pak C18 (light or plus) and cation exchange cartridges (weak or
strong) without success. In the case of the Sep-Pak C18 or weak cation exchange
cartridge, most of the radioactivity could not be trapped on the cartridges and went into
the waste. For strong cation exchange cartridge, although activity was retained in the
cartridge, the products could only be eluted only with strong basic buffer solution such as
3 N ammonia hydroxide, which is not a pharmaceutically appropriate formula for further
biological evaluations. Semi-prep HPLC with reverse phase cyano column [21] failed to
elute the products using water at 1 mL/min. Finally silica cartridges were successfully
implemented. The reaction mixture, which was diluted with water, was passed through
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the silica cartridge followed by washing with ethanol, to remove excess of precursor, and
then with 10 mL of water, to remove the residual ethanol. Final products were eluted with
saline. 5 mL of saline was required to elute 925 to 1110 Mbq (25 to 30 mCi) of product.
We measured the distribution of radioactivity after purification and found that ~70% of
activity was eluted to final product while 20% of activity went to waste, 5% stayed on
cartridge and 5% remained in the reaction vessel. The purification results were
summarized in Table 5.3.

5.2.2.3 Quality control of [11C]MEA and [11C]DMEA
It is difficult to detect N-methyl ethanolamine and N, N-dimethyl ethanolamine
using standard UV detector in HPLC system since they are not UV active. We choose to
use refractometer, which has adequate sensitivity for detection of cold standard. To
achieve the best separation between ethanolamine, N-methyl ethanolamine and N, Ndimethyl ethanolamine, we tried various HPLC conditions, such as 5 mM HCl solution,
0.25 M NaH2PO4/CH3CN mixture in different ratios and found that isocratic 0.25 M
NaH2PO4 was able to achieve best separation. The column used was strong cation
exchange column (SCX). In each case, retention time difference between the precursor
and product was more than 1 min, which made them easy to identify.

5.2.2.4 Automated synthetic module
Radiosynthesis of [11C]MEA and [11C]DMEA was carried out in an automated
synthetic module as depicted in Figure 5.7. The components in this synthetic module
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include a helium supply, ten three-way solenoid controlled flow valves, a T-shaped
reaction vessel, two collection vials (one for the waste and one for the product) and a
charcoal trap for volatile radioactivity. This automatic synthetic module requires little
manual control and could potentially be used in clinical settings.

Figure 5.7. Schematic diagram of the automated system for the production of [11C]MEA and [11C]DMEA.
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5.2.3 In vitro cell uptake studies

Figure 5.8. Cell uptake studies in PC-3 (A) and LnCap (B) prostate cancer cell lines.

After successful labeling [11C]MEA and [11C]DMEA, we first conducted the
time-dependent cell uptake studies comparing these two

11

C labeled ethanolamine

derivatives with clinically utilized [11C]CH in androgen independent PC-3 and androgen
dependent LnCap prostate cancer cell lines (Figure 5.8). The reason we chose PC-3 and
LnCap for in vitro studies is that [11C]CH is most established for imaging prostate
cancers and androgen dependence of prostate cancer cells has clinical significance for
cancer therapeutic plan and monitoring [22, 23]. Because cell uptake studies of these
tracers were done in different days on different batch of cells, most widely used PET
tracer [18F]FDG was used as a reference ligand as well. All ligands demonstrated similar
linear incremental cellular uptake in 1h time period. [11C]MEA had 1.3 (in PC-3) to 3.1
(in LnCap) fold higher uptake in comparison to [11C]CH at 60 min time point. Uptake of
[11C]DMEA in PC-3 was comparable to that of [11C]CH and 2.2 fold higher in LnCap.
All tracers had higher uptake in LnCap than in PC-3, the difference in uptake of
[11C]MEA and [11C]DMEA was much larger than [11C]CH. The uptake results suggested
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that ethanolamine derivatives [11C]MEA and [11C]DMEA could be more sensitive tracers
than [11C]CH and thus worth further investigation. Uptake studies of [11C]EA will be
conducted in the near future.

5.2.4 Inhibition studies

Figure 5.9. Inhibition studies result in PC-3 and LnCap.

We hypothesize that increased uptake of ethanolamine derivatives in cancer cells
was result of upregulated ethanolamine/choline kinase and transport activity. We then
carried out inhibition studies to characterize the uptake of tracer (Figure 5.9). It was of
interest to measure the sensitivity of tracers’ uptake to Hemicholinium 3 (HC-3) and
choline. There were studies suggesting both choline and ethanolamine were transportable
substrates of the same carrier-mediated mechanism [24]. HC-3 blocks membrane
transport of ethanolamine and choline and inhibits choline kinase (Ki = 0.5 mM) but not
ethanolamine kinase [25, 26]. Choline was a potent competitive inhibitor of ethanolamine
kinase (Ki = 0.33–0.50 mM) [27]. PC-3 or LnCap cells were subjective to the inhibitors
during preinhibition period of 10 min followed by incubation period for 60 min. The
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effect of inhibition was similar in PC-3 and LnCap cell lines. Uptake of tracers showed
concentration dependent inhibition by choline. The sensitivity to inhibitors followed the
order [11C]EA>[11C]DMEA>[11C]MEA. From this inhibition studies we could not
conclude uptake of ethanolamine and its derivatives depends on ethanolamine kinase
activity. The inhibitory effect of HC-3 was less pronounced than choline (5mM of HC-3
had similar effect as 0.5 mM choline), indicating contribution from ethanolamine kinase.

5.3 Conclusions
Based on preliminary studies with

14

C labeled ethanolamine tracers showing that

ethanolamine could be a potential oncologic imaging tracer for altered phospholipids
metabolism, we prepared positron emitting isotope labeled [11C]EA, [11C]MEA and
[11C]DMEA. Labeling of [11C]MEA and [11C]DMEA were carried out in the automatic
synthetic module that was suitable for potential clinically applications. Radiochemically
pure tracers could be obtained with good yields. In vitro cell uptake studies demonstrated
that [11C]MEA and [11C]DMEA had higher uptake than clinically utilized [11C]CH in
prostate cancer cell lines. Further development such as metabolites analysis,
biodistribution and small animal imaging studies of these
tracers is warranted.
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C labeled ethanolamine

5.4 Experimental Section
5.4.1 General
All reagents were purchased from Sigma-Aldrich and Fisher Scientific in ACS
grade. All solvents were of HPLC analytical grade. Cartridges (C18, Silica, cation
exchange) were purchased from Waters. Cancer cell lines were purchased from American
type culture collection (ATCC; Manassas, VA). All cell lines were cultured and
maintained under a 5%CO2-humidified incubator at 37ºC according to standard cell
culture protocol and in standard culture medium (GIBCO BRL, NY) recommended by
the supplier. 14C labeled tracers were purchased from American Radiolabeled Chemicals,
Inc. (ARC, St. Louis, MO). HPLC was performed on a system (Agilent Technologies
1200 series) with quaternary pump, refractometer (HP HEWLETT PACKARD series
1100), variable wavelength-detector operating at 205 nm and NaI(Tl) radiation detector
(EG&G ORTEC). The purity of all radioactive products was monitored with a strong
cation exchange column (Agilent ZORBAX 300-SCX, 5uM, 4.6x250mm) using 100%
0.25M NaH2PO4 as eluent with flow rate at 1 mL/min. Radiochemical purity was also
monitored by radio-Thin-Layer Chromatography (TLC) performed on aluminum sheets
coated with silica gel 60 F254 (0.25 mm thickness, E. Merck, Darmstadt, Germany) and
developed with MeOH/29% Ammonia hydroxide (3:1).

5.4.2 Radiochemistry
[11C] CO2 was produced by the 14N(p,α)11C nuclear reaction using a nitrogen gas
(N2/0.5%O2) target pressurized to 300 psi and bombarded with 22 MeV protons (20 min,
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10 µA) produced by the Japanese Steel Corporation (JSW) cyclotron at the Hospital of
University of Pennsylvania. [11C] MeI was then prepared from [11C] CO2 using General
Electric MeI microlab. When ready, [11C] MeI was transferred with a stream of helium
(80 mL/min) into a reaction vessel containing 1 mg of ethanolamine or N-methyl
ethanolamine in 250 µL of acetonitrile (Figure 5.6). The reaction mixture was heated at
600C for [11C]MEA or 450C for [11C]MEA for 5 mins. At the end of 5 mins of reaction,
the crude product was diluted with 3 mL of water and then passed through a silica
cartridge (preconditioned with 3 mL of 5% of ethanol in water). The cartridge was
washed with 8 mL of ethanol, 10 mL of water and then eluted with 5 mL of saline. The
radiochemical purity of products was measured by analytical HPLC (0.25 M NaH2PO4, 1
mL/min)

and

raido-TLC (NH4OH/MeOH, 1:4).

The average decay-corrected

radiochemical yield of this synthesis was 45 % (n = 4, EOB) for [11C]MEA and 52% (n =
10, EOB) for [11C]DMEA.

5.4.3 In vitro studies
Cellular uptake studies were performed using standard protocol. Briefly,
~200,000 cells were plated in 12-well tissue culture plates in triplicate and incubate for
48 hrs in growth media at which time >90% confluency was reached. On the day of study
the media was refreshed using a volume of 1 mL of media or media containing selected
inhibitors in each well. Then 1µCi of

14

C or 4µCi of

11

C labeled tracer of choice was

added to each well and incubated for specific time period (from 5 min to 1h) at 37°C and
5% CO2. Following incubation, cells were washed three times with cold PBS and lysed
with NaOH. In case of 14C labeled tracers, Sample (100 µL) of each radiotracer flask was
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mixed with liquid scintillator and the radioactivity was counted by liquid scintillation.
Experiments were performed in triplicates and the mean counts per minutes (CPM), were
calculated together with standard deviation (SD). For 11C labeled tracers, lysed cells were
collected into filter paper and counted using a gamma counter (Cobra II auto-gamma
counter D5003 spectrometer, Canberra-Packard). Protein concentration was determined
using the Lowry protein assay and uptake values was normalized by the dose
administered to each well.
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Chapter 6

Concluding Remarks and Future Directions
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6.1 Concluding Remarks
Imaging of tumor cell metabolism continues to be a cornerstone of clinical and
preclinical molecular imaging. It is not only used in tumor detection but also have
significant impact on patient management via staging and monitoring response to
therapy. Most widely used FDG-PET, which utilizes aberrant glucose metabolism in
tumor cells, had several drawbacks that make it suboptimal for imaging certain cancers
such as brain tumors and prostate cancer. A number of amino acid and choline
derivatives have been developed based on altered tumor metabolism for amino acids and
phospholipids respectively and demonstrated potential improvement over FDG in
imaging brain tumors and prostate cancer. In this thesis we prepared a series of new 18F
label tyrosine and phenylalanine derivatives (chapter 2 to chapter 4) targeting upregulated
amino acid transport activity in cancer cells. These tracers were evaluated in comparison
with clinically established tyrosine analog L-FET. Towards the end of this thesis work,
we found a potentially useful imaging agent L-FEP. It could be efficiently labeled with
good radiochemical yield and high purity. In vivo studies using rats bearing 9L tumor
model demonstrated that L-FEP is comparable to clinically used L-FET. Transport
characterization of L-FEP studies suggested that its uptake might reflect increased activity
of LAT1 in tumor cells. We have also labeled a series of

11

C labeled ethanolamine

derivatives (Chapter 5) as potential PET imaging agents utilizing altered tumor
phospholipids metabolism. Initial in vitro studies indicated ethanolamine derivatives
might have improve sensitivity over reported [11C]CH.
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6.2 Future Directions
It is still not clear that whether L-FEP would have any advantage over L-FET as
an imaging agent. To further validate the potential of L-FEP as brain imaging agents,
orthotropic brain model in rats could be used. Uptake studies of L-FEP in peripheral
tumor cell lines with high expression of LATs (R1M, HeLa et al) could be carried out to
examine its potential for imaging peripheral tumors in comparison to L-FET. Additional
studies with L-FEP can be done to confirm its selectivity for LAT1.
In vivo studies including biodistribution and small animal PET imaging studies on
PC-3 and/or LnCap xenagraft model is in progress for evaluating

11

C labeled

ethanolamine tracers. Metabolites analysis and phosphorylation studies could be
conducted to examine whether uptake of these tracers correlates with upregulation of
ethanolamine kinase and/or transport activity in Kennedy pathway.
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H and 13C NMR Spectra of compounds
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A.1 1H and 13C NMR spectra of key compounds in Chapter 2
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A.2 1H and 13C NMR spectra of key compounds in Chapter 3
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A.3 1H NMR spectra of D-isomers in Chapter 4
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